CYP11b2 inhibitor, pharmaceutical composition thereof, pharmaceutical formulation thereof, and use thereof

By designing highly active and selective CYP11B2 inhibitors, the problem of insufficient selectivity of aldosterone synthase inhibitors in existing technologies has been solved, achieving safe and effective blood pressure regulation and treatment of aldosterone-related diseases.

WO2026238031A1PCT designated stage Publication Date: 2026-11-19JUMPCAN (SHANGHAI) MEDICAL TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096886
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-11
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

In existing technologies, aldosterone synthase inhibitors lack selectivity, resulting in inhibition of cortisol synthase, causing side effects, and making it difficult to effectively treat uncontrolled hypertension and related diseases.

Method used

To develop a CYP11B2 inhibitor with high activity and selectivity, through the design of compounds with specific structures, to inhibit aldosterone synthase and avoid interference with cortisol synthase, thus providing a safer treatment option.

Benefits of technology

It effectively reduced blood pressure and plasma aldosterone levels while minimizing the impact on cortisol synthesis, thus lowering the risk of hypertension and related diseases, and has potential clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096886_19112026_PF_FP_ABST
    Figure CN2026096886_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure belongs to the technical field of pharmaceuticals, and relates to a CYP11B2 inhibitor, a pharmaceutical composition thereof, a pharmaceutical formulation thereof, and use thereof. The inhibitor is a compound represented by formula (I), which has relatively strong inhibitory activity and relatively high selectivity against CYP11B2, and can be used for treating, preventing, or alleviating related diseases mediated by CYP11B2.
Need to check novelty before this filing date? Find Prior Art

Description

CYP11B2 inhibitors and their pharmaceutical compositions, formulations and applications

[0001] Cross-reference to related applications

[0002] This application claims priority and benefits from the following Chinese patent applications, the entire contents of which are incorporated herein by reference:

[0003] Chinese patent application No. 202510631080.9, entitled "CYP11B2 inhibitor and pharmaceutical composition thereof, pharmaceutical formulation and application", was filed with the China National Intellectual Property Administration on May 15, 2025.

[0004] Chinese patent application No. 202511302138.1, entitled "CYP11B2 Inhibitor and Pharmaceutical Composition, Pharmaceutical Formulation and Application", was filed with the China National Intellectual Property Administration on September 11, 2025. Technical Field

[0005] This disclosure belongs to the field of pharmaceutical technology, specifically relating to a CYP11B2 inhibitor and its pharmaceutical composition, pharmaceutical formulation and application. Background Technology

[0006] Uncontrolled hypertension (UH) refers to hypertension in which blood pressure cannot be controlled despite treatment with one or two antihypertensive drugs, while refractory hypertension (RH) refers to hypertension in which blood pressure cannot be controlled despite treatment with three or more antihypertensive drugs, including diuretics. Uncontrolled hypertension (including refractory hypertension) accounts for 20%-35% of all hypertension cases. Although awareness, treatment, and control rates of hypertension have improved in recent years, they remain at a low level overall. The global hypertension control rate is approximately 20%, and this figure is even lower in low- and middle-income countries. Persistent uncontrolled hypertension significantly increases the risk of stroke, chronic kidney disease, myocardial infarction, and heart failure, and is a major risk factor for premature death from cardiovascular disease worldwide.

[0007] Aldosterone is secreted by the zona glomerulosa of the adrenal glands and its genetic and non-genetic regulatory effects can be mediated through mineralocorticoid receptor-dependent and independent pathways. Under physiological conditions, aldosterone regulates the reabsorption of sodium ions and excretion of potassium ions by the kidneys, as well as water retention, maintaining the body's water-electrolyte balance and blood pressure homeostasis. However, under pathological conditions, excessive aldosterone secretion can promote inflammation, fibrosis, adverse remodeling, and functional disorders in the heart, blood vessels, and kidneys, leading to the occurrence and progression of various aldosterone-related diseases. Therefore, inhibiting aldosterone function is a promising strategy for treating aldosterone-related diseases. Compared to inhibiting the mineralocorticoid receptors that mediate aldosterone-mediated effects, aldosterone synthase inhibitors have certain advantages in terms of safety and efficacy.

[0008] Aldosterone synthase (CYP11B2) is expressed in the zona glomerulosa of the adrenal gland and participates in the last three steps of aldosterone synthesis, making it a key enzyme in the aldosterone biosynthesis pathway. Inhibiting CYP11B2 can block aldosterone synthesis, simultaneously inhibiting both mineralocorticoid receptor-dependent and non-dependent pathways, providing a more thorough inhibition of aldosterone function compared to mineralocorticoid receptor antagonists. Furthermore, inhibiting aldosterone synthesis preserves basal mineralocorticoid receptor function, reducing the risk of hyperkalemia. 11-β-hydroxylase (CYP11B1) is expressed in the zona fasciculata of the adrenal gland and participates in cortisol synthesis. The amino acid sequences of CYP11B2 and CYP11B1 share 93% homology, and their enzyme active sites have extremely high sequence similarity, posing a significant challenge to the development of selective CYP11B2 inhibitors. Early developed aldosterone synthase inhibitors, lacking selectivity, easily resulted in off-target inhibition of CYP11B1, leading to suppressed cortisol synthesis and significant side effects such as metabolic disorders and gonadal dysfunction.

[0009] Osilodrostat (also known as LCI-699) was one of the earlier non-selective aldosterone synthase inhibitors to enter clinical development. It effectively inhibits aldosterone synthesis and lowers blood pressure, but it also inhibits CYP11B1, thus interfering with cortisol synthesis, which ultimately prevented its approval for hypertension treatment. Lorundrostat and Baxdrostat are the two most advanced CYP11B2 selective inhibitors in clinical trials. Clinical studies have shown that they effectively lower plasma aldosterone levels and blood pressure, while having no substantial effect on plasma cortisol levels. Preclinical data show that Lorundrostat has stronger inhibitory activity and selectivity against CYP11B2 compared to Baxdrostat. Furthermore, Lorundrostat has achieved success in a phase III clinical trial for uncontrolled hypertension and is expected to become the first marketed selective aldosterone synthase inhibitor.

[0010] Because aldosterone is closely associated with a variety of diseases, the clinical benefits of selective CYP11B2 inhibitors can not only reduce the risk of cardiovascular-related diseases and complications, but also be extended to other aldosterone-related indications in the future, such as chronic kidney disease and obstructive sleep apnea, generating greater clinical value.

[0011] Therefore, the development of highly active and selective CYP11B2 inhibitors is of great significance in addressing unmet clinical needs related to aldosterone-related diseases. Summary of the Invention

[0012] The problem this disclosure aims to solve

[0013] This disclosure aims to provide a CYP11B2 inhibitor with high activity and selectivity, pharmaceutical compositions thereof, pharmaceutical formulations and applications thereof.

[0014] Solution for solving the problem

[0015] In a first aspect, this disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels:

[0016] in,

[0017] Ring A is selected from 5-10 membered heteroaromatic rings and 5-10 membered saturated or partially saturated heteroalicylic rings, each of which contains 1-3 N atoms;

[0018] R 1 The group is selected from H, halogen, -SF5, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl and 3-6 membered heterocyclic alkyl containing 1-3 heteroatoms selected from N, O and S, wherein each cycloalkyl or heterocyclic alkyl is optionally substituted by 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy;

[0019] m is selected from 0, 1, 2, and 3;

[0020] If it exists, each R 2 Each is independently selected from halogens, hydroxyl groups, and C1-C6 alkyl groups;

[0021] L is selected from *-C(R) 7 R 8 )-C(=O)-, *-OC(=O)- and *-C(O)-C(R 7 R 8 )-, where one end of the "*" mark is connected to ring B, and the other end is connected to -NR 4 R5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms to which they are attached, they form a 3-5 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups and C1-C6 alkoxy groups;

[0022] Ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L;

[0023] Each Each bond can be a single bond or a double bond independently, and they cannot both be double bonds at the same time;

[0024] X 1 Selected from C, CH, CR 3 and N, X 2 Selected from CH2, CHR 3 NH, CH and N, X 3 Selected from CH2, CHR 3 NH, CH and N, under the condition that: X 1 X 2 X 3 They are not both N at the same time, and they satisfy the valence bond rule;

[0025] Y is selected from CR 6 and N; if they exist, R 6 Selected from H, halogens, and hydroxyl groups;

[0026] n is selected from 0, 1, and 2;

[0027] If it exists, each R 3 Each is independently selected from C1-C6 alkyl and oxo groups; or,

[0028] When n=2, there are 2 R 3 Attached to the same C atom of ring B and interconnected with each other, forming an 8-12 member saturated or partially saturated spirocyclic or heterospirocyclic ring together with ring B, wherein each spirocyclic or heterospirocyclic ring is optionally substituted by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or,

[0029] When n=2, there are 2 R 3Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated or partially saturated fused aliphatic ring or fused heteroaliphatic ring together with ring B. Each fused aliphatic ring or fused heteroaliphatic ring is optionally substituted with 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0030] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to each other and together with ring B forms a 7-10 saturated or partially saturated bridged ring or heterobridged ring, wherein each bridged ring or heterobridged ring is optionally replaced by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups and C1-C6 alkoxy groups;

[0031] R 4 For H; R 5 The alkyl group is a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 haloalkyl group, a C4-C11 cycloalkyl group, a C5-C9 bridged cycloalkyl group, or a 4-11 membered heterocyclic alkyl group containing 1-3 heteroatoms selected from N, O, and S. Each of the cycloalkyl, bridged cycloalkyl, or heterocyclic alkyl groups is optionally surrounded by 1-3 atoms selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)O. The heterocyclic or heteroaryl group is substituted with a group selected from N, O, and S and optionally substituted with a group selected from halogen, oxo, hydroxyl, C1-C6 alkyl, and C1-C6 alkoxy groups; or,

[0032] R 4 R 5The N atoms bonded to them together form 4-11 membered heterocyclic groups, which additionally contain 0-3 heteroatoms selected from N, O, and S and optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic groups, 5-10 membered heteroaryl groups, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', - The 3-8-membered heterocyclic group or 5-10-membered heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups;

[0033] If present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0034] In some implementations, R 1 The group is selected from H, F, Cl, Br, -SF5, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy and C3-C6 cycloalkyl, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy.

[0035] In some implementations, R 1 The group is selected from H, -SF5, cyano, C1-C4 alkyl, C1-C4 haloalkyl and C3-C5 cycloalkyl, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogen, C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 alkoxy.

[0036] In some implementations, R 1 The group is selected from cyano, -SF5, C1-C4 alkyl and C3-C5 cycloalkyl, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F, C1-C2 alkyl, C1-C2 fluoroalkyl and C1-C2 alkoxy.

[0037] In some implementations, R 1 The group is selected from cyano, -SF5, C1-C2 alkyl and C3-C4 cycloalkyl, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F, C1-C2 alkyl, trifluoromethyl, difluoromethyl and monofluoromethyl.

[0038] In some implementations, R 1 The group is selected from -SF5, C1-C2 alkyl and C3-C4 cycloalkyl, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F.

[0039] In some implementations, R 1 The group is selected from -SF5 and C3-C6 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C6 alkyl groups.

[0040] In some implementations, R 1 The group is selected from -SF5 and C3-C5 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C4 alkyl groups.

[0041] In some implementations, R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from F.

[0042] In some implementations, R 1 Selected from -SF5 and cyclopropyl, wherein the cyclopropyl group is optionally replaced by 1-2 groups selected from F.

[0043] In some implementations, R 1 It is selected from cyano, -SF5, methyl, cyclopropyl, 1-fluorocyclopropyl, 2,2-difluorocyclopropyl, 1,2-difluorocyclopropyl, 2,3-difluorocyclopropyl, 1-methylcyclopropyl, 2,2-dimethylcyclopropyl, 1,2-dimethylcyclopropyl and 2,3-dimethylcyclopropyl.

[0044] In some implementations, R 1 It is selected from cyano, -SF5, methyl, cyclopropyl and 2,2-difluorocyclopropyl.

[0045] In some implementations, R 1 Selected from -SF5, cyclopropyl and 2,2-difluorocyclopropyl.

[0046] In some implementations, R 1 It is a methyl group.

[0047] In some implementations, R 1 It is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy groups.

[0048] In some implementations, R 1It is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C6 alkyl groups.

[0049] In some implementations, R 1 It is a C3-C5 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0050] In some implementations, R 1 It is a C3-C4 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0051] In some implementations, R 1 The cyclopropyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0052] In some implementations, R 1 The cyclopropyl group is optionally replaced by a group selected from F and methyl.

[0053] In some implementations, R 1 The cyclopropyl group is optionally replaced by two F groups.

[0054] In some implementations, R 1 It is 2,2-difluorocyclopropyl.

[0055] In some implementations, R 1 for

[0056] In some implementations, R 1 It is located at the 2, 3, or 4 position of the benzene ring.

[0057] In some implementations, R 1 It is located at position 4 of the benzene ring.

[0058] In some embodiments, ring A is selected from 5-6 membered heteroaromatic rings and 5-10 membered saturated or partially saturated heteroalicylic rings, each of which contains 1-3 N atoms.

[0059] In some embodiments, ring A is selected from 5-6 membered heteroaromatic rings and 5-10 membered saturated or partially saturated heteroalicylic rings, each of which contains 2-3 N atoms.

[0060] In some embodiments, ring A is selected from 5-6 membered heteroaromatic rings and 5-8 membered partially saturated heteroalicylic rings, each of which contains 2-3 N atoms.

[0061] In some embodiments, ring A is a 5-6 membered heteroaromatic ring containing 1-3 N atoms.

[0062] In some embodiments, ring A is selected from 5-6 membered heteroaromatic rings containing 2-3 N atoms.

[0063] In some embodiments, ring A is selected from pyridine rings, pyridazine rings, pyrazine rings, 1,2,4-triazole rings, 1,2,3-triazine rings, 1,2,4-triazine rings, 1,3,5-triazine rings, and partially saturated pyrazolopyrrole rings.

[0064] In some implementations, ring A is selected from... in, One end of the marker is connected to the benzene ring. One end of the mark is connected to ring B; ring A is also connected to -(R 2 ) m Connections; if they exist, each R 2 The radical is independently selected from halogens, hydroxyl groups, and C1-C6 alkyl groups; m is selected from 0, 1, 2, and 3.

[0065] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the mark is connected to ring B; ring A is also connected to -(R 2 ) m Connections; if they exist, each R 2 Independently selected from halogens, hydroxyl groups, and C1-C6 alkyl groups; m is 0 or 1.

[0066] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B.

[0067] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B, R 2 Selected from halogens, hydroxyl groups, and C1-C6 alkyl groups.

[0068] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the mark is connected to ring B; ring A is also connected to -(R 2 ) m Connections; each R 2Independently selected from halogens and hydroxyl groups, and m is selected from 1 and 2; preferably, R 2 Selected from halogens and hydroxyl groups, and m is 1; more preferably, R 2 It is a halogen, and m is 1.

[0069] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B; R 2 It is a halogen; preferably, R 2 It is chlorine.

[0070] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the mark is connected to ring B; ring A is also connected to -(R 2 ) m Connection; if it exists, R 2 Selected from halogens, hydroxyl groups, and C1-C6 alkyl groups; m is 0 or 1.

[0071] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B.

[0072] In some implementations, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B.

[0073] In some implementations, if present, each R 2 It is independently selected from halogens, hydroxyl groups, and C1-C4 alkyl groups.

[0074] In some implementations, if present, each R 2 It is independently selected from halogens, hydroxyl groups, and C1-C3 alkyl groups.

[0075] In some implementations, if present, each R 2 It is independently selected from halogens and hydroxyl groups.

[0076] In some implementations, if present, each R 2 Halogens are independent of each other.

[0077] In some implementations, if present, each R 2 It is independently selected from F, Cl and Br.

[0078] In some implementations, if R exists2 It is Cl.

[0079] In some implementations, m is selected from 0, 1, and 2.

[0080] In some implementations, m is selected from 0 and 1.

[0081] In some implementations, m is 0.

[0082] In some implementations, m is 1.

[0083] In some implementations, L is selected from *-C(R) 7 R 8 )-C(=O)-, *-OC(=O)- and *-C(O)-C(R 7 R 8 )-, where one end of the "*" mark is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms to which they are attached, they form a 3-5 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0084] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms to which they are attached, they form a 3-5 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0085] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8Together with the C atoms to which they are attached, they form a 3-4 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.

[0086] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms they are attached to, they form cyclopropane groups.

[0087] In some implementations, L is selected from *-C(R) 7 R 8 )-C(=O)- and *-C(O)-C(R) 7 R 8 )-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H and deuterium.

[0088] In some implementations, L is selected from *-C(R) 7 R 8 )-C(=O) and *-C(O)-C(R) 7 R 8 )-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Both are H, or R 7 R 8 All are deuterium.

[0089] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Both are H, or R 7 R 8 All are deuterium.

[0090] In some implementations, L is *-C(R) 7 R8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 All are H.

[0091] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 All are deuterium.

[0092] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Together with the C atoms they are attached to, they form 3-5 member aliphatic rings.

[0093] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Together with the C atoms they are attached to, they form 3-4 membered aliphatic rings.

[0094] In some implementations, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Together with the C atoms they are attached to, they form cyclopropane groups.

[0095] In some implementations, L is *-C(=O)-C(R) 7 R 8 )-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 For H.

[0096] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; each Each can be a single or double bond independently, but not both simultaneously; X 1 For C, CH or N, X 2 X 3 Each is independently CH or CH2, and satisfies the valence bond rule; Y is CR. 6 Or N, if it exists, R 6 It can be H, halogen, or hydroxyl.

[0097] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L, X 1 For C, CH or N, Represents a single or double bond, satisfying the valence bond rule; Y represents CR. 6 Or N, if it exists, R 6 It can be H, halogen, or hydroxyl.

[0098] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L, X 1 Y is CH or N; Y is CR 6 Or N, if it exists, R 6 It can be H, halogen, or hydroxyl.

[0099] In some implementations, ring B is selected from...

[0100] in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0101] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0102] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0103] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0104] In some implementations, if present, each R 3 It is independently selected from C1-C6 alkyl and oxo groups.

[0105] In some implementations, if present, each R 3 It is independently selected from C1-C2 alkyl and oxo compounds.

[0106] In some implementations, if present, each R 3 It is independently selected from C1-C2 alkyl groups.

[0107] In some implementations, if R exists 3 It is an oxygen-based process.

[0108] In some implementations, n is selected from 0, 1, and 2.

[0109] In some implementations, n is 0.

[0110] In some implementations, n is 1.

[0111] In some implementations, n is 2.

[0112] In some implementations, if R exists 6 Selected from H, halogens, and hydroxyl groups.

[0113] In some implementations, if R exists 6 Selected from halogens and hydroxyl groups.

[0114] In some implementations, if R exists 6 Selected from F, Cl, Br and hydroxyl groups.

[0115] In some implementations, if R exists 6 Selected from F and hydroxyl groups.

[0116] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2; or,

[0117] When n=2, there are 2 R 3Attached to the same C atom of ring B and interconnected with each other, forming an 8-11 saturated heterospirocycle together with ring B, wherein the heterospirocycle is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or,

[0118] When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated fused heteroalicylic ring together with ring B. The fused heteroalicylic ring is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0119] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to the other and together with ring B forms a 7-9 saturated heterobridged ring, wherein the heterobridged ring is optionally substituted by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0120] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C4 alkyl and oxo; n is selected from 0, 1, and 2; or,

[0121] When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated fused heteroalicylic ring together with ring B. The fused heteroalicylic ring is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0122] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to the other and together with ring B forms a 7-9 saturated heterobridged ring, wherein the heterobridged ring is optionally substituted by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0123] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from methyl and oxo; n is selected from 0, 1 and 2.

[0124] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0125] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0126] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0127] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; n = 2, and there are 2 Rs. 3 They are respectively attached to two adjacent C atoms of ring B and interconnected, forming 7-membered, 8-membered, 9-membered or 10-membered saturated fused heteroalicylic rings together with ring B.

[0128] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0129] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0130] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; n = 2, and there are 2 Rs. 3 They are respectively attached to two non-adjacent C atoms of ring B and connected to each other, forming a 7-membered, 8-membered or 9-membered saturated heterobridged ring together with ring B.

[0131] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0132] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0133] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0134] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0135] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0136] In some implementations, ring B is selected from... in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0137] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; R 6 Selected from H, halogens, and hydroxyl groups; if present, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2; or,

[0138] When n=2, there are 2 R 3 Attached to the same C atom of ring B and interconnected with each other, forming an 8-11 saturated heterospirocycle together with ring B, wherein the heterospirocycle is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or,

[0139] When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated fused heteroalicylic ring together with ring B. The fused heteroalicylic ring is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0140] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to the other and together with ring B forms a 7-9 saturated heterobridged ring, wherein the heterobridged ring is optionally substituted by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0141] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; R 6 Selected from H, halogens, and hydroxyl groups; if present, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2.

[0142] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; R 6 Selected from H, halogens, and hydroxyl groups; if present, R 3 For oxygenation; n is selected from 0, 1, and 2.

[0143] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; R 6 Selected from H, F, and hydroxyl groups; if present, R 3 For oxygenation; n is selected from 0, 1, and 2.

[0144] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0145] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0146] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0147] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2; or,

[0148] When n=2, there are 2 R 3Attached to the same C atom of ring B and interconnected with each other, forming an 8-11 saturated heterospirocycle together with ring B, wherein the heterospirocycle is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or,

[0149] When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated fused heteroalicylic ring together with ring B. The fused heteroalicylic ring is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0150] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to the other and together with ring B forms a 7-9 saturated heterobridged ring, wherein the heterobridged ring is optionally replaced by 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.

[0151] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2.

[0152] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is 0.

[0153] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; n = 2, and there are 2 Rs. 3 They are respectively attached to two adjacent C atoms of ring B and interconnected, forming 7-membered, 8-membered, 9-membered or 10-membered saturated fused heteroalicylic rings together with ring B.

[0154] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0155] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2; or,

[0156] When n=2, there are 2 R 3 Attached to the same C atom of ring B and interconnected with each other, forming an 8-11 member partially saturated heterospirocycle together with ring B, wherein the heterospirocycle is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or,

[0157] When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming an 8-10 quintic partially saturated fused heteroalicylic ring together with ring B. The fused heteroalicylic ring is optionally substituted with 1-3 groups selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or...

[0158] When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to the other and together with ring B forms a 7-9 quintile partially saturated heterobridged ring, wherein the heterobridged ring is optionally substituted by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups.

[0159] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2.

[0160] In some implementations, ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L.

[0161] In some implementations, R 4 For H; R 5Selected from C4-C11 cycloalkyl groups and 4-11 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, wherein each cycloalkyl or heterocycloalkyl group is optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocycloyl, 5-9 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC The heterocyclic or heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0162] In some implementations, R 4 For H; R 5 The compounds are selected from C4-C9 cycloalkyl groups and 4-9 membered heterocyclic alkyl groups containing 1-3 heteroatoms selected from N, O, and S, wherein each cycloalkyl or heterocyclic alkyl group is optionally surrounded by 1-3 atoms selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The heterocyclic or heteroaryl group is substituted with one to three heteroatoms selected from N, O and S and optionally substituted with one to two groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0163] In some implementations, R 4 For H; R 5The compounds are selected from C5-C6 cycloalkyl groups and 5-6-membered heterocyclic alkyl groups containing 1-2 heteroatoms selected from N and O, wherein each cycloalkyl or heterocyclic alkyl group is optionally surrounded by 1-2 atoms selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6-membered heterocyclic group, 5-6-membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The heterocyclic or heteroaryl group is substituted with one or two heteroatoms selected from N and O and optionally substituted with one or two groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0164] In some implementations, R 4 For H; R 5 The cyclohexyl, cyclopentyl, or cyclobutyl group is optionally surrounded by 1-3 groups selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic group, 5-10 membered heteroaryl group, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R' ... The heterocyclic or heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from 1 to 2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0165] In some implementations, R 4 For H; R 5The cyclohexyl group is optionally surrounded by 1-3 groups selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic group, 5-10 membered heteroaryl group, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, - The heterocyclic or heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from 1 to 2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0166] In some implementations, R 4 For H; R 5 for Each R 9 Each group is independently selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C(=O)NR 'OR', -OP(=O)R'2, -OP(=O)(OR')2, and -OP(=O)(NR'2)2, wherein the heterocyclic or heteroaryl group contains 1-3 heteroatoms selected from N, O, and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl, and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl; p is 1 or 2. In some specific embodiments, the heterocyclic group is selected from...

[0167] In some implementations, R 4 For H; R 5 for Each R 9Each group is independently selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C(=O)NR 'OR', -OP(=O)R'2, -OP(=O)(OR')2 and -OP(=O)(NR'2)2, wherein the heterocyclic or heteroaryl group contains 1-3 heteroatoms selected from N, O and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; p is 1 or 2.

[0168] In some implementations, R 4 For H; R 5 for R 9 The heterocyclic or heteroaryl group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, wherein the heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl, and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl; p is 1. In some specific embodiments, the heterocyclic group is selected from

[0169] In some implementations, R 4 For H; R 5 for R 9The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, wherein the heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; p is 1.

[0170] In some implementations, R 4 For H; R 5 for R 9 The heterocyclic or heteroaryl group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', and -C(=O)NR'2. The heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted with 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl, and C1-C6 alkoxy groups. If present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, and C3-C6 cycloalkyl. In some specific embodiments, the heterocyclic group is selected from...

[0171] In some implementations, R 4 For H; R 5 for R 9 The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR' and -C(=O)NR'2, wherein the heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0172] In some implementations, R 4 For H; R 5 for R 9 The heterocyclic group is selected from 3-6 membered heterocyclic groups and -NHC(=O)R', wherein the heterocyclic group contains 1-2 N atoms and is optionally substituted with one oxo group; if present, R' is selected from C1-C6 alkyl and C1-C6 deuterated alkyl groups. In some specific embodiments, the heterocyclic group is selected from...

[0173] In some implementations, R 4 For H; R 5 for R 9 The heterocyclic group is selected from 3-6 membered heterocyclic groups and -NHC(=O)R', wherein the heterocyclic group contains 1-2 N atoms and is optionally substituted with one oxo group; if present, R' is selected from C1-C6 alkyl and C1-C6 deuterated alkyl groups. In some specific embodiments, the heterocyclic group is selected from...

[0174] In some implementations, R 4 For H; R 5 Selected from R 9 The group is selected from oxo, 3-6 membered heterocyclic, 5-6 membered heteroaryl, -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0175] In some implementations, R 4 For H; R 5 Selected from R 9 The heterocyclic group is selected from 3-6 membered heterocyclic groups, -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the heterocyclic group contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C4 alkyl, C1-C4 deuterated alkyl, C1-C4 haloalkyl and C3-C6 cycloalkyl.

[0176] In some implementations, R 4 For H; R 5 Selected from R 9 Selected from and -NHC(=O)R'; if present, each R' is independently selected from C1-C4 alkyl and C1-C4 deuterated alkyl.

[0177] In some implementations, R 4 For H; R 5 Selected from R 9 Selected from and -NHC(=O)R'; if present, each R' is independently methyl, isopropyl or deuterated methyl.

[0178] In some implementations, R 4 For H; R 5 for R 9 It is -NHC(=O)R'; R' is selected from C1-C4 alkyl and C1-C4 deuterated alkyl.

[0179] In some implementations, R 4 For H; R 5 for R 9 It is -NHC(=O)R'; R' is methyl, isopropyl or deuterated methyl.

[0180] In some implementations, R 4 For H; R 5 for R 9 It is -NHC(=O)R'; R' is selected from C1-C4 alkyl and C1-C4 deuterated alkyl.

[0181] In some implementations, R 4 For H; R 5 for R 9 It is -NHC(=O)R'; R' is methyl, isopropyl or deuterated methyl.

[0182] In some implementations, R 4 For H; R 5 for R 9 It is -NHC(=O)R'; R' is methyl.

[0183] In some implementations, R 4 For H; R 5 for R 9The group is selected from 3-6 membered heterocyclic groups, 5-6 membered heteroaryl groups, -C(=O)R', -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the heterocyclic or heteroaryl group contains 1-2 heteroatoms selected from N and O and is optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0184] In some implementations, R 4 For H; R 5 for R 9 Selected from oxo, -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR'; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; p is 1 or 2.

[0185] In some implementations, R 4 For H; R 5 for

[0186] In some implementations, R 4 R 5 The N atoms bonded to them together form 4-11 membered heterocyclic groups, which additionally contain 0-3 heteroatoms selected from N, O, and S and optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic groups, 5-9 membered heteroaryl groups, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, - The 3-6-membered heterocyclic group or 5-9-membered heteroaryl group is substituted with 1-3 heteroatoms selected from N, O and S and optionally substituted with 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0187] In some implementations, R 4 R 5The N atoms bonded to them together form 4-11 membered heterocyclic groups, which additionally contain 0-3 heteroatoms selected from N, O, and S and optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic groups, 5-6 membered heteroaryl groups, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(= The 3-6 membered heterocyclic group or 5-6 membered heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0188] In some implementations, R 4 R 5 The N atoms bonded to them together form 4-9 membered heterocyclic groups, which additionally contain 0-3 heteroatoms selected from N, O, and S and optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic groups, 5-6 membered heteroaryl groups, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The 3-6-membered heterocyclic group or 5-6-membered heteroaryl group contains 1-3 heteroatoms selected from N, O and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0189] In some implementations, R 4 R 5The N atoms bonded to them together form a 5-6 membered heterocyclic group, which additionally contains 0-2 heteroatoms selected from N and O and optionally surrounded by 1-2 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic group, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The 3-6-membered heterocyclic group or 5-6-membered heteroaryl group is substituted with 1-2 heteroatoms selected from N and O and optionally substituted with 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0190] In some implementations, R 4 R 5 The N atoms bonded to them together form a 5-6 membered heterocyclic group, which additionally contains 0-1 heteroatoms selected from N and optionally surrounded by 1-2 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic group, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The 3-6 membered heterocyclic group or 5-6 membered heteroaryl group is substituted with one or two heteroatoms selected from N and O and optionally substituted with one or two groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0191] In some implementations, when ring B is At that time, R 4 R 5The N atoms bonded to them together form a 5-6 membered heterocyclic group, which additionally contains 0-1 heteroatoms selected from N and optionally surrounded by 1-2 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-6 membered heterocyclic group, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O) The 3-6 membered heterocyclic group or 5-6 membered heteroaryl group is substituted with one or two heteroatoms selected from N and O and optionally substituted with one or two groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0192] In some implementations, R 4 R 5 The N atoms connected to them together form Each R 10 Independently selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C(=O)NR 'OR', -OP(=O)R'2, -OP(=O)(OR')2 and -OP(=O)(NR'2)2, wherein the 3-8 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-3 heteroatoms selected from N, O and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; q is 1 or 2.

[0193] In some implementations, R 4 R 5 The N atoms connected to them together form R 10The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR' and -C(=O)NR'2, wherein the 3-6 membered heterocyclic or 5-6 membered heteroaryl contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; q is 1.

[0194] In some implementations, R 4 R 5 The N atoms connected to them together form R 10 The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR' and -C(=O)NR'2, wherein the 3-6 membered heterocyclic or 5-6 membered heteroaryl contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0195] In some implementations, R 4 R 5 The N atoms connected to them together form R 10 The group is selected from 3-6-membered heterocyclic groups, 5-6-membered heteroaryl groups, -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the 3-6-membered heterocyclic group or the 5-6-membered heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0196] In some implementations, when ring B is At that time, R 4 R 5 The N atoms connected to them together form R 10 The group is selected from 3-6-membered heterocyclic groups, 5-6-membered heteroaryl groups, -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the 3-6-membered heterocyclic group or the 5-6-membered heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0197] In some implementations, when ring B is At that time, R 4 R 5 The N atoms connected to them together form R 10 It is -NHC(=O)R'; R' is a C1-C6 alkyl group.

[0198] In some implementations, when ring B is At that time, R 4 R 5 The N atoms connected to them together form R 10 It is -NHC(=O)R'; R' is a C1-C4 alkyl group.

[0199] In some implementations, R 4 R 5 The N atoms connected to them together form Each R 11 Independently selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C(=O)NR 'OR', -OP(=O)R'2, -OP(=O)(OR')2 and -OP(=O)(NR'2)2, wherein the 3-8 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-3 heteroatoms selected from N, O and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; t is 1 or 2.

[0200] In some implementations, R 4 R 5The N atoms connected to them together form R 11 The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR' and -C(=O)NR'2, wherein the 3-6 membered heterocyclic or 5-6 membered heteroaryl contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl; t is 1.

[0201] In some implementations, R 4 R 5 The N atoms connected to them together form R 11 The group is selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-6 membered heterocyclic, 5-6 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR' and -C(=O)NR'2, wherein the 3-6 membered heterocyclic or 5-6 membered heteroaryl contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxy, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0202] In some implementations, R 4 R 5 The N atoms connected to them together form R 11 The group is selected from 3-6-membered heterocyclic groups, 5-6-membered heteroaryl groups, R', -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the 3-6-membered heterocyclic group or the 5-6-membered heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0203] In some implementations, when ring B is At that time, R 4R 5 The N atoms connected to them together form R 11 The group is selected from 3-6-membered heterocyclic groups, 5-6-membered heteroaryl groups, R', -NHC(=O)R', -NHS(=O)2R' and -NHC(=O)OR', wherein the 3-6-membered heterocyclic group or the 5-6-membered heteroaryl group contains 1-2 heteroatoms selected from N and O and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0204] In some implementations, when ring B is At that time, R 4 R 5 The N atoms connected to them together form R 11 R' is a C1-C6 haloalkyl group.

[0205] In some implementations, when ring B is At that time, R 4 R 5 The N atoms connected to them together form R 11 R' is a C1-C4 haloalkyl group.

[0206] In some implementations, R 4 For H; R 5 The bridged ring is a C5-C9 bridging ring, wherein the bridged ring is optionally surrounded by 1-3 groups selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C( The 3-8 membered heterocyclic group or 5-10 membered heteroaryl group is replaced by a group selected from N, O and S and optionally replaced by a group selected from 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0207] In some implementations, R 4For H; R 5 The bridged ring is a C5-C8 bridged ring group, wherein the bridged ring group is optionally surrounded by 1-2 groups selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic group, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C( The 3-8 membered heterocyclic group or 5-10 membered heteroaryl group is replaced by a group selected from N, O and S and optionally replaced by a group selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0208] In some implementations, R 4 For H; R 5 Selected from R 12 Selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', -C(=O)OR', -C(=O)NR'2, -OC(=O)R', -OC(=O)NR'2, -C(=O)NR'OR' -OP(=O)R'2, -OP(=O)(OR')2 and -OP(=O)(NR'2)2, wherein the 3-8 membered heterocyclic group or the 5-10 membered heteroaryl group contains 1-2 heteroatoms selected from N, O and S and optionally substituted by 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; if present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0209] In some implementations, R 4 For H; R 5 Selected from R 12 It is -NHC(=O)R'; R' is selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

[0210] In some implementations, R 4 For H; R 5 Selected from R 12 It is -NHC(=O)R'; R' is a C1-C4 alkyl group, or R' is methyl, isopropyl or deuterated methyl.

[0211] In some implementations, R 4 For H; R 5 Selected from R 12 It is -NHC(=O)R'; R' is methyl.

[0212] In some implementations, R 4 For H; R 5 for Cy is selected from C4-C6 saturated aliphatic rings and C5-C8 bridged rings; T is -C(=O)- or -S(=O)2-; R 13 For H and R 14 It is a C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl, or, R 13 and R 14 Interconnection makes Formation of 4-6 membered heterocyclic groups.

[0213] In some implementations, R 4 For H; R 5 for Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl, C1-C4 deuterated alkyl, or C1-C4 haloalkyl, or, R 13 and R 14 Interconnection makes form

[0214] In some implementations, R 4 For H; R 5 for Cy is in, One end of the mark and Connection; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl, C1-C4 deuterated alkyl, or C1-C4 haloalkyl, or, R 13 and R 14 Interconnection makes form

[0215] In some implementations, R 4 For H; R 5 for Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form

[0216] In some implementations, R 4 For H; R 5 for Cy is in, One end of the mark and Connection; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form

[0217] In some implementations, R 4 For H; R 5 for Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl.

[0218] In some implementations, R 4 For H; R 5 for Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It can be methyl, isopropyl, or deuterated methyl.

[0219] In some implementations, R 4 For H; R 5It is selected from C1-C6 alkyl, C1-C6 deuterated alkyl, and C1-C6 haloalkyl.

[0220] In some implementations, R 4 For H; R 5 It is a C1-C4 alkyl, C1-C4 deuterated alkyl, or C1-C4 haloalkyl.

[0221] In some implementations, R 4 For H; R 5 It is a C1-C3 alkyl or a C1-C3 deuterated alkyl.

[0222] In some implementations, R 4 For H; R 5 It is isopropyl.

[0223] In some embodiments, the compound of formula (I) above is further shown as in formula (I-1):

[0224] In the compound shown in formula (I-1), L and X 1 X 2 X 3 Y, R 1 R 3 R 4 R 5 The definitions of n are as described in equation (I).

[0225] In some embodiments, the compound of formula (I) above is further shown as in formula (I-2):

[0226] In the compound shown in formula (I-2), L and X 1 Y, R 1 R 3 R 4 R 5 The definitions of n are as described in equation (I).

[0227] In some embodiments, the compound of formula (I) above is further shown as in formula (I-3):

[0228] In the compound shown in formula (I-3), L and R 1 R 3 R 4 R 5 The definitions of n are as described in equation (I).

[0229] In some embodiments, the compound of formula (I) above is further shown as in formula (I-4):

[0230] In the compound shown in formula (I-4), R 1 R 3 The definitions of R' and n are as described in equation (I).

[0231] In some embodiments, the compound of formula (I) above is further shown as in formula (I-4-a):

[0232] In the compound represented by formula (I-4-a), R 1 R 3 R 7 R 8 The definitions of R' and n are as described in formula (I). In some embodiments, the compound of formula (I) above is further shown as in formula (I-5):

[0233] In the compound shown in formula (I-5), R 1 The definitions of R and R' are as described in equation (I).

[0234] In some embodiments, the compound of formula (I) above is further shown as in formula (I-5-a):

[0235] In the compound represented by formula (I-5-a), R 1 R 7 R 8 The definitions of R and R' are as described in equation (I).

[0236] In some embodiments, the compound of formula (I) above is further shown as in formula (I-6):

[0237] In the compound shown by formula (I-6), R 1 The definition is as described in equation (I).

[0238] In some embodiments, the compound of formula (I) above is further shown as in formula (I-6-a):

[0239] In the compound represented by formula (I-6-a), R 1 R 7 and R 8 The definition is as described in equation (I).

[0240] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1The group is selected from H, halogen, -SF5, cyano, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl and 3-6 membered heterocyclic alkyl containing 1-3 heteroatoms selected from N, O and S, wherein each cycloalkyl or heterocyclic alkyl is optionally substituted with 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy.

[0241] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The group is selected from -SF5 and C3-C6 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C6 alkyl groups.

[0242] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The group is selected from -SF5 and C3-C5 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C4 alkyl groups.

[0243] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The group is selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F and methyl.

[0244] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with 1-2 F atoms.

[0245] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with two F atoms.

[0246] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1It is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy groups.

[0247] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 It is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C6 alkyl groups.

[0248] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 It is a C3-C6 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C4 alkyl groups.

[0249] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 It is a C3-C5 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0250] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 It is a C3-C4 cycloalkyl group, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0251] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The cyclopropyl group is optionally replaced by 1-2 groups selected from F and C1-C2 alkyl groups.

[0252] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The cyclopropyl group is optionally replaced by a group selected from F and methyl.

[0253] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 The cyclopropyl group is optionally replaced by two F groups.

[0254] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 Selected from -SF5, cyclopropyl and 2,2-difluorocyclopropyl.

[0255] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), formula (I-5-a), formula (I-6), or formula (I-6-a), R 1 for

[0256] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5) or formula (I-5-a), R' is a C1-C6 alkyl or a C1-C6 deuterated alkyl.

[0257] In some embodiments, R' is a C1-C6 alkyl group in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5), or formula (I-5-a).

[0258] In some embodiments, R' is a C1-C4 alkyl group in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5) or formula (I-5-a).

[0259] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5) or formula (I-5-a), R' is a C1-C4 alkyl or a C1-C4 deuterated alkyl.

[0260] In some embodiments, in the compounds represented by formula (I-4), formula (I-4-a), formula (I-5) or formula (I-5-a), R' is methyl, isopropyl or deuterated methyl.

[0261] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups.

[0262] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R8 Each is independently selected from H, deuterium, and C1-C4 alkyl groups.

[0263] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R 8 Each is independently selected from H, deuterium, and C1-C2 alkyl groups.

[0264] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R 8 Each is independently selected from H and deuterium.

[0265] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R 8 For H.

[0266] In some embodiments, in the compounds represented by formula (I-4-a), formula (I-5-a), or formula (I-6-a), R 7 and R 8 It is deuterium.

[0267] In some embodiments, the compound of formula (I) above is further shown as in formula (I-7):

[0268] In the compounds shown in formula (I-7), ring B is defined as described in formula (I).

[0269] In some embodiments, the compound of formula (I) above is further shown as in formula (I-8):

[0270] In the compound shown in formula (I-8), R 4 R 5 The definition is as described in equation (I).

[0271] In some embodiments, in the compounds represented by formula (I-8), R 4 For H, R 5 for R 9 Selected from p is 1.

[0272] In some implementations, R 4 For H; R 5 for R 9 Selected from p is 1.

[0273] In some implementations, R 4 For H; R 5 for R 9 Selected from

[0274] In some implementations, R 4 For H; R 5 for R 9 Selected from

[0275] In some implementations, R 4 For H; R 5 for R 9 Selected from

[0276] In some implementations, R 4 For H; R 5 for R 9 Selected from

[0277] In some embodiments, the compound of formula (I) above is further shown as in formula (I-9):

[0278] In the compound shown in formula (I-9), R 1 R 4 R 7 R 8 Cy, T, R 13 and R 14 The definition is as described in equation (I).

[0279] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C6 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogens and C1-C6 alkyl groups; R 4 H; Cy is selected from C4-C6 saturated aliphatic rings and C5-C8 bridged rings; T is -C(=O)- or -S(=O)2-; R 13 For H and R 14 It is a C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl, or, R 13 and R 14 Interconnection makes Formation of 4-6 membered heterocyclic groups; R 7 R 8Each can be H or deuterium independently.

[0280] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C5 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogens and C1-C4 alkyl groups; R 4 H; Cy is selected from C4-C6 saturated aliphatic rings and C5-C8 bridged rings; T is -C(=O)- or -S(=O)2-; R 13 For H and R 14 It is a C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl, or, R 13 and R 14 Interconnection makes Formation of 4-6 membered heterocyclic groups; R 7 R 8 Each can be H or deuterium independently.

[0281] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C5 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogens and C1-C4 alkyl groups; R 4 H is; Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0282] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C5 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogens and C1-C4 alkyl groups; R 4 H is; Cy is in, One end of the mark and Connection; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R7 R 8 Each can be H or deuterium independently.

[0283] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with 1-2 groups selected from F and methyl; R 4 H is; Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0284] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with 1-2 groups selected from F and methyl; R 4 H is; Cy is in, One end of the mark and Connection; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0285] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with 1-2 F atoms; R 4 H is; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R7 R 8 Each can be H or deuterium independently.

[0286] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is optionally substituted with 1-2 F atoms; R 4 H is; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0287] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5 and C3-C4 cycloalkyl groups, wherein the cycloalkyl group is substituted with 1-2 halogens; R 4 H is; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0288] In some embodiments, in the compounds represented by formula (I-9), R 1 Selected from -SF5, cyclopropyl and 2,2-difluorocyclopropyl; R 4 For H; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0289] In some embodiments, in the compounds represented by formula (I-9), R 1 It is 2,2-difluorocyclopropyl; R 4 H is; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form R 7 R 8 Each can be H or deuterium independently.

[0290] In some embodiments, in the compounds represented by formula (I-9), R 1 It is 2,2-difluorocyclopropyl; R 4 H is; Cy is in One end of the mark and Connected; T is -C(=O)-; R 13 For H and R 14 It is methyl, isopropyl, or deuterated methyl; R 7 R 8 All are H or all are deuterium.

[0291] Secondly, this disclosure provides the following compounds or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled compounds:

[0292] Thirdly, this disclosure provides a method for preparing the compound disclosed herein.

[0293] The compounds disclosed herein can generally be prepared or isolated by synthetic and / or semi-synthetic methods known to those skilled in the art, or by methods described in detail in the embodiments herein.

[0294] In some embodiments, the compounds disclosed herein are typically prepared according to the following general methods:

[0295] General preparation method one:

[0296] Wherein, X is a halogen, preferably Cl or Br; PG is an amino protecting group; the definitions of other variables in formulas (IM-1), (IM-2), (IM-3), (IM-4), (IM-5), and (I') are as described in formula (I) above.

[0297] In the general preparation method one, formulas (IM-1) and (IM-2) are reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (IM-3). Formula (IM-3) is then reacted with a catalyst and a solvent to remove the amino protecting group, yielding formula (IM-4). Formulas (IM-4) and (IM-5) are then reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (I').

[0298] General preparation method two:

[0299] Wherein, X is a halogen, preferably Cl or Br; PG is an amino protecting group; the definitions of other variables in formulas (IM-1), (IM-2), (IM-5), (IM-6), (IM-7), and (I') are as described in formula (I) above.

[0300] In the second general preparation method, formulas (IM-2) and (IM-5) are reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (IM-6). Formula (IM-6) is then reacted with a catalyst and a solvent to remove the amino protecting group, yielding formula (IM-7). Formulas (IM-7) and (IM-1) are reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (I').

[0301] General preparation method three:

[0302] Wherein, X is a halogen, preferably Cl or Br; Alk is a C1-C4 alkyl group; the definitions of other variables in formulas (IM-1), (IM-8), (IM-9), (IM-10), (IM-11) and (I') are as described in formula (I) above.

[0303] In general preparation method three, formulas (IM-1) and (IM-8) are reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (IM-9). Formula (IM-9) is then subjected to ester hydrolysis in the presence of a base and a solvent to yield formula (IM-10). Formulas (IM-10) and (IM-11) are reacted via a conventional condensation reaction in the presence of a condensing agent and a solvent to yield formula (I').

[0304] General preparation method four:

[0305] Wherein, X is a halogen, preferably Cl or Br; BP is... PG is an amino protecting group; the definitions of other variables in formulas (IM-1), (IM-5), (IM-12), (IM-13), (IM-14) and (I”) are as described in formula (I) above.

[0306] In the general preparation method four, formulas (IM-1) and (IM-12) are reacted via a conventional Suzuki coupling reaction in the presence of a base, a palladium catalyst, and a solvent to yield formula (IM-13). Formula (IM-13) is then reacted with a catalyst and a solvent to remove the amino protecting group, yielding formula (IM-14). Formulas (IM-14) and (IM-5) are reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (I”).

[0307] General preparation method five:

[0308] Wherein, X is a halogen, preferably Cl or Br; PG is an amino protecting group; the definitions of other variables in formulas (IM-1), (IM-11), (IM-15), (IM-16), (IM-17) and (I”') are as described in formula (I) above.

[0309] In general preparation method five, formulas (IM-15) and (IM-11) are reacted via a conventional condensation reaction in the presence of a condensing agent and a solvent to yield formula (IM-16). Formula (IM-16) is then reacted with a catalyst and a solvent to remove the amino protecting group, yielding formula (IM-17). Formulas (IM-17) and (IM-1) are then reacted via a conventional nucleophilic substitution reaction in the presence of a base and a solvent to yield formula (I”').

[0310] Fourthly, this disclosure provides a pharmaceutical composition comprising the compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, or the compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label.

[0311] In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.

[0312] In some embodiments, the pharmaceutically acceptable excipients include (but are not limited to) fillers, disintegrants, surfactants, and solubilizers.

[0313] Fifthly, this disclosure provides a pharmaceutical formulation comprising the compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, or the compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, or the pharmaceutical composition described in the fourth aspect.

[0314] In some embodiments, the pharmaceutical preparation includes (but is not limited to) tablets, capsules, granules, sugar-coated pills, powders, lozenges, powder injections, liquid preparations, and suppositories.

[0315] In some embodiments, the administration routes of the pharmaceutical preparation include (but are not limited to) oral, topical, rectal, parenteral, inhalation, and implantation.

[0316] Sixthly, this disclosure provides the use of the compounds described in the first aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect in the preparation of medicaments for regulating (preferably inhibiting) 11-β hydroxylase (CYP11B1) and / or aldosterone synthase (CYP11B2).

[0317] In some embodiments, the drug is a drug for selectively regulating (preferably inhibiting) aldosterone synthase (CYP11B2).

[0318] The compounds disclosed herein, or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled derivatives, exhibit excellent inhibitory activity against aldosterone synthase (CYP11B2), with a half-maximal inhibitory concentration (IC50) for this enzyme. 50 The concentrations are 0.01–5 μM, or 0.01–500 nM, or 0.01–300 nM, or 0.05–100 nM, or 0.1–50 nM, or 0.1–10 nM, or 0.1–1 nM, or 1–10 nM.

[0319] The compounds disclosed herein, or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled derivatives, exhibit excellent selectivity for aldosterone synthase (CYP11B2). This selectivity can be measured by the IC50 values ​​of the compounds, or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled derivatives, against 11-β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2). 50The ratio is used to calculate, typically 1 to 10,000 times, or 300 to 8,000 times, or 300 to 5,000 times, or 200 to 5,000 times, or 1,000 to 5,000 times, or 3,000 to 5,000 times, or 3,000 to 4,000 times.

[0320] In a seventh aspect, this disclosure provides the use of the compounds described in the first aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect in the preparation of medicaments for treating, preventing or alleviating diseases mediated by aldosterone synthase.

[0321] In some embodiments, this disclosure provides the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or pharmaceutical compositions described in the fourth aspect or pharmaceutical preparations described in the fifth aspect, for the treatment, prevention or relief of diseases mediated by aldosterone synthase.

[0322] In some embodiments, this disclosure provides a method for treating, preventing, or alleviating diseases mediated by aldosterone synthase, comprising: administering a compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a pharmaceutical composition described in the fourth aspect, or a pharmaceutical formulation described in the fifth aspect, to an individual in need.

[0323] In some embodiments, the aldosterone synthase-mediated diseases described in this disclosure include (but are not limited to): primary aldosteronism, secondary aldosteronism, hypertension, heart failure, cardiomyopathy, cardiac hypertrophy (including left ventricular hypertrophy, etc.), myocardial infarction, myocardial necrosis, myocardial ischemia-reperfusion injury, coronary artery disease, myocardial or vascular fibrosis or remodeling (including cardiovascular fibrosis and remodeling associated with hypertension and / or endothelial dysfunction, etc.), restenosis, vascular wall thickening, arteriosclerosis, renal failure (including chronic renal failure, etc.), acute kidney injury, chronic kidney disease, renal fibrosis, nephropathy (including diabetic nephropathy, etc.), hypokalemia, obesity, metabolic syndrome, sleep apnea syndrome, retinopathy (including diabetic retinopathy, etc.), liver disease, lipid metabolism disorders, sympathetic hyperactivity, sudden and / or periodic edema, headache, anxiety disorders, and depressive disorders, etc.

[0324] In some embodiments, the primary aldosteronism in this disclosure includes (but is not limited to) unilateral or bilateral adrenal adenoma, unilateral or bilateral adrenal hyperplasia, aldosterone-producing adrenal carcinoma, unilateral adrenal multinodular aldosteronism, glucocorticoid-responsive aldosteronism, familial aldosteronism, and ectopic aldosterone-producing tumors.

[0325] In some embodiments, the secondary aldosteronism in this disclosure includes (but is not limited to) hypertension caused by estrogen preparations, renovascular hypertension, pregnancy-induced hypertension, malignant hypertension, pheochromocytoma, congestive heart failure, pseudohypoaldosteronism, chronic liver disease (including cirrhosis, etc.) with ascites, and hyperaldosteronism.

[0326] In some embodiments, in this disclosure, the hyperaldosteronism is hyperaldosteronism resulting from the inappropriate use of drugs such as laxatives or diuretics, nephrotic syndrome, Bartter syndrome, or Gitelman's syndrome.

[0327] In some embodiments, the hypertension described in this disclosure includes (but is not limited to) primary hypertension, secondary hypertension (including renovascular hypertension, renal parenchymal hypertension, primary aldosteronism, pheochromocytoma, sleep apnea syndrome, Cushing's syndrome, drug-induced hypertension, aortic stenosis, and hyperparathyroidism), uncontrolled hypertension, refractory hypertension, resistory hypertension (RfH), obesity-related hypertension, and mineralocorticoid-related hypertension.

[0328] In some embodiments, the heart failure described in this disclosure includes (but is not limited to) congestive heart failure, left ventricular failure, right ventricular failure, systolic dysfunction, and diastolic dysfunction.

[0329] In some embodiments, this disclosure provides the use of the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or pharmaceutical compositions described in the fourth aspect or pharmaceutical preparations described in the fifth aspect in the preparation of medicaments for treating, preventing or alleviating primary aldosteronism, secondary aldosteronism, hypertension, heart failure, arteriosclerosis or nephropathy.

[0330] In some embodiments, this disclosure provides the use of the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or pharmaceutical compositions described in the fourth aspect or pharmaceutical preparations described in the fifth aspect in the preparation of medicaments for treating, preventing or alleviating primary aldosteronism, secondary aldosteronism, hypertension or nephropathy.

[0331] In some embodiments, this disclosure provides the use of the compounds described in the first aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the compounds described in the second aspect or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect in the preparation of medicaments for treating, preventing or alleviating hypertension or kidney disease.

[0332] In some embodiments, this disclosure provides the use of the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect in the preparation of medicaments for treating, preventing or alleviating hypertension.

[0333] In some embodiments, this disclosure provides the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or pharmaceutical compositions described in the fourth aspect or pharmaceutical preparations described in the fifth aspect for treating, preventing or relieving hypertension.

[0334] In some embodiments, this disclosure provides a method for treating, preventing, or alleviating hypertension, comprising: administering a compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a pharmaceutical composition described in the fourth aspect, or a pharmaceutical formulation described in the fifth aspect, to an individual in need.

[0335] In some specific embodiments, the drug further comprises one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers.

[0336] In some embodiments, this disclosure provides the use of the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect in the preparation of a medicament for use in combination with one or more active therapeutic agents to treat, prevent or relieve hypertension, wherein the active therapeutic agent is selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and calcium channel blockers.

[0337] In some specific implementations, the hypertension is uncontrolled hypertension.

[0338] In some specific implementations, the hypertension is refractory hypertension.

[0339] In some specific implementations, the hypertension is refractory hypertension.

[0340] In some specific embodiments, the hypertension is uncontrolled hypertension, and the drug further comprises one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers.

[0341] In some specific embodiments, the hypertension is refractory hypertension, and the drug further comprises one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers.

[0342] In some specific embodiments, the hypertension is refractory hypertension, and the drug further comprises one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers.

[0343] Eighthly, this disclosure provides the use of the compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the pharmaceutical composition described in the fourth aspect or the pharmaceutical formulation described in the fifth aspect in the preparation of a medicament for treating, preventing or alleviating hypertension in an individual in need; wherein the individual has taken one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and calcium channel blockers before taking the compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs or isotopic labels, or the pharmaceutical composition described in the fourth aspect or the pharmaceutical formulation described in the fifth aspect.

[0344] In some embodiments, this disclosure provides the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the compounds described in the second aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect, for the treatment, prevention or relief of hypertension in an individual in need; said individual having previously taken one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and calcium channel blockers before taking the compounds described in the first aspect or pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, solvates, prodrugs or isotopic labels thereof, or the pharmaceutical compositions described in the fourth aspect or the pharmaceutical formulations described in the fifth aspect.

[0345] In some embodiments, this disclosure provides a method for treating, preventing, or alleviating hypertension in an individual in need, comprising: administering a compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a compound described in the second aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels, or a pharmaceutical composition described in the fourth aspect, or a pharmaceutical preparation described in the fifth aspect, to an individual in need; the individual taking the present disclosure. Prior to taking one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers, the compound described in the first aspect or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels thereof, or the pharmaceutical composition described in the fourth aspect or the pharmaceutical formulation described in the fifth aspect, the individual has taken the compound in question.

[0346] In some implementations, the hypertension is uncontrolled hypertension.

[0347] In some implementations, the hypertension is refractory hypertension.

[0348] In some implementations, the hypertension is refractory hypertension.

[0349] In some embodiments, the diuretic in this disclosure is selected from indapamide, clopamide, chlorthalidone, hydrochlorothiazide, mefcitrate, metoprazone, and meteclaron.

[0350] In some embodiments, the angiotensin-converting enzyme (ACE) inhibitors of this disclosure are selected from captopril, enalapril, perindopril, benazepril, fosinopril, cilazapril, ramipril, midapril, lisinopril, and benazepril.

[0351] In some embodiments, the angiotensin II receptor blocker (ARB) of this disclosure is selected from olmesartan, candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan.

[0352] In some embodiments, the calcium channel blockers of this disclosure are selected from amlodipine besylate, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisodipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, sinidipine, manidipine, miradipine, benprodipine, barnidipine, nivardipine, golopamil, lidocaine, areradipine, and dotazine.

[0353] The effect of this disclosure

[0354] This disclosure provides a compound that can be used as a CYP11B2 inhibitor, said compound having strong inhibitory activity against CYP11B2 and high selectivity. The compound's half-maximal inhibitory concentration (IC50) for CYP11B2 is specified. 50 The concentrations are 0.01–5 μM, 0.01–500 nM, 0.01–300 nM, 0.05–100 nM, 0.1–50 nM, 0.1–10 nM, or 1–10 nM. The selectivity of the compound for CYP11B2 can be determined by the IC50 values ​​of the compound for CYP11B1 and for CYP11B2. 50 The ratio is typically calculated as 1–10,000 times, or 300–8,000 times, or 300–5,000 times, or 1,000–5,000 times, or 3,000–5,000 times, or 3,000–4,000 times. Furthermore, the compounds disclosed herein possess excellent pharmacokinetic properties and safety, are readily marketable, and can be used to treat, prevent, or alleviate diseases mediated by aldosterone synthase. Detailed Implementation

[0355] Various exemplary embodiments, features, and aspects of this disclosure will be described in detail below. The term "exemplary" as used herein means "serving as an example, embodiment, or illustration." Any embodiment illustrated herein as "exemplary" is not necessarily to be construed as superior to or better than other embodiments.

[0356] Furthermore, to better illustrate this disclosure, numerous specific details are set forth in the following detailed description. Those skilled in the art will understand that this disclosure can be practiced without certain specific details. In other instances, methods, means, apparatus, and steps well known to those skilled in the art have not been described in detail in order to highlight the main points of this disclosure.

[0357] Unless otherwise stated, all units used in this specification are international standard units, and all numerical values ​​and ranges appearing in this disclosure should be understood to include systematic errors that are unavoidable in industrial production.

[0358] In this specification, the word "may" has two meanings: to perform a certain process and not to perform a certain process.

[0359] In this specification, the terms "some embodiments," "some specific / preferred embodiments," "other specific / preferred embodiments," and "implementation" refer to specific elements (e.g., features, structures, properties, and / or characteristics) related to that embodiment, which are included in at least one of the embodiments described herein and may or may not be present in other embodiments. Furthermore, it should be understood that these elements may be combined in any suitable manner in various embodiments.

[0360] Terminology Explanation:

[0361] In this specification, the range of values ​​referred to as "value A to value B" refers to the range including the endpoint values ​​A and B.

[0362] In this disclosure, when "room temperature" or "room temperature" is used, the temperature can be 15-30°C or 15-25°C, such as 20°C.

[0363] As used herein, the term "halogen" refers to F, Cl, Br, or I.

[0364] As used herein, the term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group consisting only of carbon and hydrogen atoms, having a specified number of carbon atoms, and connected to the rest of the molecule by single bonds.

[0365] As used herein, the term "alkoxy" refers to a group of the formula -OR, where R is an alkyl group having a specified number of carbon atoms, and the "alkyl" has the definition above.

[0366] As used herein, the term "cycloalkyl" refers to a non-aromatic monocyclic, bicyclic, or polycyclic fused saturated cyclic group consisting only of carbon and hydrogen atoms and having a specified number of cyclic atoms, which is connected to the rest of the molecule via a single bond through the cyclic carbon atom. For the purposes of this disclosure, "cycloalkyl" can be monocyclic or bicyclic fused, preferably monocyclic.

[0367] As used herein, the term "alicylic ring" refers to a non-aromatic monocyclic, bicyclic, or polycyclic fused saturated or partially saturated cyclic group consisting only of carbon and hydrogen atoms and having a specified number of cyclic atoms, which is connected to the rest of the molecule via single bonds through the cyclic carbon atoms. For the purposes of this disclosure, an "alicylic ring" can be monocyclic or bicyclic fused, preferably monocyclic.

[0368] As used herein, the term "heterocyclic alkyl" refers to a non-aromatic, monocyclic, bicyclic, or polycyclic fused saturated cyclic group having a specified number of cyclic atoms, wherein the cyclic atoms consist of a carbon atom and one or more heteroatoms (such as nitrogen, oxygen, and sulfur), wherein the cyclic carbon atom or cyclic heteroatom (such as sulfur) may optionally be oxidized, and is connected to the remainder of the molecule via a single bond through the cyclic carbon atom or cyclic heteroatom. For the purposes of this disclosure, a "heterocyclic alkyl" may be monocyclic or bicyclic fused, preferably monocyclic. When the "heterocyclic alkyl" is bicyclic fused and the number of cyclic heteroatoms is greater than or equal to 2, the cyclic heteroatoms may be all located on one ring or may be located on different rings.

[0369] As used herein, the term "heteroalicylic ring" refers to a non-aromatic, monocyclic, bicyclic, or polycyclic fused saturated or partially saturated cyclic group having a specified number of cyclic atoms, wherein the cyclic atoms consist of carbon and one or more heteroatoms (such as nitrogen, oxygen, and sulfur), wherein the cyclic carbon atom or cyclic heteroatom (such as sulfur) may optionally be oxidized, and is connected to the remainder of the molecule via a single bond through the cyclic carbon atom or cyclic heteroatom. For the purposes of this disclosure, the "heteroalicylic ring" can be monocyclic or bicyclic fused, preferably monocyclic. When the "heteroalicylic ring" is bicyclic fused and the number of cyclic heteroatoms is greater than or equal to 2, the cyclic heteroatoms may all be located on one ring or on different rings. When the "heteroalicylic ring" is bicyclic fused, neither monocyclic ring is aromatic.

[0370] As used herein, the term "heterocyclic group" refers to a saturated or partially saturated cyclic group having a specified number of cyclic atoms in a monocyclic, bicyclic, or polycyclic fusion, wherein the cyclic atoms consist of carbon and one or more heteroatoms (such as nitrogen, oxygen, and sulfur), wherein the cyclic carbon atom or cyclic heteroatom (such as sulfur) may optionally be oxidized and is connected to the remainder of the molecule via a single bond. For the purposes of this disclosure, a "heterocyclic group" may be a monocyclic or bicyclic fusion, preferably monocyclic. When the "heterocyclic group" is bicyclic fusion and the number of cyclic heteroatoms is greater than or equal to 2, the cyclic heteroatoms may be all located on one ring or on different rings. When the "heterocyclic group" is bicyclic fusion, neither ring is aromatic, or one ring is aromatic and the other is not.

[0371] As used herein, the term "heteroaryl ring" or "heteroaryl group" refers to an aromatic cyclic group having a specified number (e.g., 5-10) of cyclic atoms, the cyclic atoms being composed of a carbon atom and one or more heteroatoms (such as nitrogen, oxygen, and sulfur), and being connected to the rest of the molecule via single bonds through the cyclic carbon atom or the cyclic heteroatom. For the purposes of this disclosure, a "heteroaryl ring" or "heteroaryl group" can be monocyclic or bicyclic / polycyclic fused. When the "heteroaryl ring" or "heteroaryl group" is bicyclic or polycyclic fused and the number of cyclic heteroatoms is greater than or equal to 2, the cyclic heteroatoms can be located on the same ring or on different rings. When a "heteroaryl ring" or "heteroaryl group" is substituted with a hydroxyl group, its keto tautomer also belongs to the "heteroaryl ring" or "heteroaryl group" of this disclosure; for example, the "heteroaryl ring" or "heteroaryl group" of this disclosure can be 2-pyridone, 4-pyridone, etc. However, when a keto tautomer is used as a substituent, if it cannot be converted to an enol tautomer, then the keto tautomer is non-aromatic, meaning it does not fall under the definition of a "heteroaromatic ring" or "heteroaryl group," but rather the definition of a "heterocyclic group." For example, when the nitrogen atom in a 2-pyridone or 4-pyridone group is attached to the rest of the molecule, it is considered non-aromatic. It does not fall under the definition of "heterocyclic ring" or "heteroaryl", but rather under the definition of "heterocyclic group".

[0372] As used herein, the term "spirocyclic" or "spirocyclic group" refers to a polycyclic system in which the monocyclic rings share a single carbon atom (spiro atom), which is connected to the rest of the molecule via single bonds through the ring-forming atom. The ring-forming atom does not contain heteroatoms and can be saturated (without double or triple bonds) or unsaturated (containing one or more double or triple bonds), but neither monocyclic ring possesses aromaticity. Spirocyclic systems are classified as monospirocyclic, bispirocyclic, or polyspirocyclic based on the number of shared spiro atoms between the rings. For the purposes of this disclosure, "spirocyclic" can be monospirocyclic or bispirocyclic, preferably monospirocyclic.

[0373] As used herein, the term "heterospirocyclic" or "heterospirocyclic group" refers to a polycyclic system in which monocyclic rings share a single carbon atom (spiro atom), which is connected to the rest of the molecule via single bonds through the cyclic atom. The cyclic atom contains at least one heteroatom selected from nitrogen, oxygen, and sulfur, and can be saturated (containing no double or triple bonds) or unsaturated (containing one or more double or triple bonds), but none of the monocyclic rings is aromatic. Heterospirocyclic rings are classified into mono-heterospirocyclic, di-heterospirocyclic, or poly-heterospirocyclic rings based on the number of shared spiro atoms between the rings. For the purposes of this disclosure, mono-heterospirocyclic and di-heterospirocyclic rings are preferred.

[0374] As used herein, the term "bridged ring" or "bridged ring group" refers to a polycyclic system in which 3- to 15-membered monocyclic rings share two or more non-adjacent cyclic atoms, which are connected to the rest of the molecule via single bonds through the cyclic atoms. The cyclic atoms do not contain heteroatoms and can be saturated (without double or triple bonds) or unsaturated (with one or more double or triple bonds), but neither monocyclic ring is aromatic.

[0375] As used herein, the term "heterobridged ring" or "heterobridged cyclic group" refers to a polycyclic system of 3- to 15-membered monocycles sharing two or more non-adjacent cyclic atoms, which are connected to the rest of the molecule via single bonds through the cyclic atoms. The cyclic atoms contain at least one heteroatom selected from nitrogen, oxygen, and sulfur, and can be saturated (without double or triple bonds) or unsaturated, but none of the monocycles are aromatic.

[0376] As used herein, the term "halogenated" refers to the replacement or substitution of one or more hydrogen atoms in a defined group by a halogen.

[0377] As used herein, the term "saturated" means that all carbon atoms in a defined chain group are connected by single bonds, or that all cyclic atoms in a defined cyclic group are connected by single bonds; "partially saturated" means that at least two carbon atoms in a defined chain group are connected by double or triple bonds, or that at least two cyclic atoms in a defined cyclic group are connected by double or triple bonds, excluding cases where the cyclic group is fully aromatic.

[0378] The modifiers preceding "alkyl", "alkoxy", etc., such as "C1-C4" and "C3-C6", refer to the range of the number of carbon atoms contained in the defined group.

[0379] The modifiers preceding the aforementioned groups such as "cycloalkyl", "heterocycloalkyl", and "heteroaryl", such as "3-6", "4-7", and "6-10", refer to the range of the number of cyclic atoms contained in the defined group.

[0380] As used herein, the terms “optionally” or “optionally” mean that the event described thereafter may or may not occur. For example, a group “optionally substituted with 1-2 halogens” is unsubstituted, substituted with 1 halogen, or substituted with 2 halogens.

[0381] As used herein, the term "independently" means that at least two groups (or ring systems) in a structure with the same or similar value ranges can have the same or different definitions under specific circumstances. For example, if substituent X and substituent Y are independently hydrogen, halogen, hydroxyl, cyano, alkyl, or aryl, then when substituent X is hydrogen, substituent Y can be hydrogen, halogen, hydroxyl, cyano, alkyl, or aryl; similarly, when substituent Y is hydrogen, substituent X can be hydrogen, halogen, hydroxyl, cyano, alkyl, or aryl.

[0382] As used herein, the term "pharmaceutically acceptable salt" means a salt that is physiologically free from undue toxicity, irritation, or allergic reactions. Substances used for salt formation may be acids or bases, wherein acids include inorganic or organic acids that can form salts with the basic groups in the compounds disclosed herein; and bases include inorganic or organic bases that can form salts with the acidic groups in the compounds disclosed herein.

[0383] Unless otherwise specified, the compounds disclosed herein include all possible stereoisomers and tautomers (e.g., enol and keto forms). Stereoisomers in this disclosure include optical isomers (e.g., enantiomers, diastereomers, epimers), cis-trans isomers (e.g., Z-type and E-type), and conformational isomers. Furthermore, single stereoisomers or tautomers, as well as mixtures of stereoisomers and tautomers, are all within the scope of this disclosure.

[0384] As used herein, the term "optical isomer" refers to a stable isomer that has a perpendicular asymmetric plane due to having at least one chiral element (including a chiral center, chiral axis, chiral plane, etc.), thereby enabling the rotation of plane-polarized light. Because the compounds of this disclosure contain asymmetric centers and other chemical structures that may lead to stereoisomerism, this disclosure also includes such stereoisomers and mixtures thereof. Because the compounds and salts of this disclosure include asymmetric carbon atoms, they can exist as single stereoisomers, racemates, and mixtures of enantiomers and diastereomers. The term "enantiomer" refers to a pair of stereoisomers that have mirror images of each other that cannot be superimposed. The term "diastereomer" or "diastereomer" refers to an optical isomer that does not form a mirror image of each other. The term "racemic mixture" or "racemate" refers to a mixture containing equal parts of a single enantiomer (i.e., an equimolar mixture of two R and S enantiomers). In particular, if a molecule has a center of symmetry, a plane of symmetry, or an axis of symmetry, then the molecule will not possess chirality. For example, In this molecule, because there is a plane passing through the C-1 and C-4 atoms and perpendicular to the six-membered ring, it can divide the molecular structure into two mirror-image parts, thus the molecule does not possess chirality.

[0385] As used herein, the term "cis-trans isomer" refers to stereoisomers formed by the different positions of atoms (or groups) on opposite sides of a double bond or ring system relative to a reference plane; in the cis isomer (trans-), the atoms (or groups) are on the same side of the double bond or ring system, and in the trans isomer (cis-), the atoms (or groups) are on opposite sides of the double bond or ring system. For example, In cyclohexane, when the R and R' groups are located on the same side of the cyclohexane plane, it is a cis (cis-) isomer. It indicates that when the R and R' groups are located on opposite sides of the cyclohexane plane, it is a trans isomer. This is indicated. Those skilled in the art will understand that... These four drawing methods are equivalent to each other and can all be used to represent cis isomers in which the R and R' groups are located on the same side of the cyclohexane plane; These four drawing methods are equivalent to each other and can all be used to represent trans isomers with R and R' groups located on opposite sides of the cyclohexane plane.

[0386] Unless otherwise stated, all cis-trans isomers of the compounds disclosed herein are within the scope of this disclosure.

[0387] As used herein, the term "conformal isomer," also known as "rotational isomer," refers to the different spatial arrangements of atoms or groups resulting from the rotation of single bonds; for example, cyclohexane has two conformational isomers: the boat conformation and the chair conformation. Unless otherwise stated, all conformational isomers of the compounds disclosed herein are within the scope of this disclosure.

[0388] As used herein, the term "tautomer," also known as "tautomer form," refers to structural isomers with different energies that can interconvert through a low energy barrier. If tautomerism is possible (e.g., in solution), chemical equilibrium can be achieved in the tautomer. For example, proton tautomers (or proton transfer tautomers) include (but are not limited to) interconversions via proton transfer, such as keto-enol isomerization, imine-enamine isomerization, amide-imine alcohol isomerization, etc. Unless otherwise stated, all tautomer forms of the compounds disclosed herein are within the scope of this disclosure.

[0389] As used herein, the term "solvent" refers to a substance formed by the combination of a compound of the present disclosure or a pharmaceutically acceptable salt thereof with at least one solvent molecule through non-covalent intermolecular forces. The term "solvent" includes "hydrate". Common solvates include (but are not limited to) hydrates (e.g., hemihydrates, monohydrates, dihydrates, trihydrates, etc.), ethanol compounds, acetone compounds, etc.

[0390] As used herein, the term "prodrug" refers to a derivative compound that, when administered to a subject, can directly or indirectly provide the compounds of this disclosure. Particularly preferred are derivative compounds or prodrugs that, when administered to a subject, can improve the bioavailability of the compounds of this disclosure (e.g., facilitate absorption into the bloodstream) or promote the delivery of the parent compound to its site of action (e.g., the lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of this disclosure are within the scope of this disclosure, and various prodrug forms are well known in the art.

[0391] As used herein, the term "isotope label" refers to a compound in which one or more atoms in a molecule are replaced by atoms with atomic or mass numbers different from those normally found in nature. Isotopes commonly used as isotope labels include, but are not limited to: hydrogen isotopes: deuterium (…). 2 H) and tritium ( 3 H); Carbon isotopes: 11 C 13 C and 14 C; Chlorine isotopes: 35 Cl and 37 Cl; Fluorine isotopes: 18 F; Iodine isotopes: 123 I and 125 I; Nitrogen isotopes:13 N and 15 N; oxygen isotopes: 15 O、 17 O and 18 O; and sulfur isotopes: 35 S.

[0392] As used in this article, the term "refractory hypertension" refers to hypertension that, despite intensive lifestyle interventions, requires simultaneous use of three different types of antihypertensive medications (including a thiazide diuretic) for ≥4 weeks at maximum dose or the patient's maximum tolerated dose. This includes conditions such as office blood pressure ≥140 / 90 mmHg and a 24-hour ambulatory blood pressure average ≥130 / 80 mmHg or a home blood pressure average ≥135 / 85 mmHg, or the need to take ≥4 antihypertensive medications to achieve target blood pressure. For details, please refer to the *Guidelines for the Prevention and Treatment of Hypertension in China (2024 Revised Edition)* (Chinese Journal of Hypertension (Chinese and English), July 2024, Vol. 32, No. 7, pp. 603-700).

[0393] As used in this article, the term "refractory hypertension" refers to hypertension that remains uncontrolled despite the use of ≥5 antihypertensive medications (including thiazide diuretics and aldosterone receptor antagonists). For details, please refer to the "Guidelines for the Prevention and Treatment of Hypertension in China (2024 Revised Edition)" (Chinese Journal of Hypertension (Chinese and English), July 2024, Vol. 32, No. 7, pp. 603-700).

[0394] This disclosure further prepares specific compounds using the following methods. Unless otherwise specified, the compounds, reagents, etc., used in the embodiments of this disclosure are purchased from qualified suppliers or synthesized with reference to methods disclosed in the prior art.

[0395] abbreviation:

[0396] Unless otherwise stated or the context otherwise requires, the following abbreviations in this specification shall be understood to have the following meanings:

[0397] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.

[0398] Example

[0399] The structure of the compound was determined by nuclear magnetic resonance and / or mass spectrometry.

[0400] NMR chemical shift (δ) with respect to 10 -6 The unit (ppm) is given. NMR measurements were performed using a BRUKER AVANCE NEO 400MHz NMR spectrometer. The solvents used were DMSO-d6, CDCl3, and CD3OD, and the internal standard was TMS.

[0401] MS measurements were performed using an Agilent 1260 / G6125C.

[0402] HPLC analysis was performed using an Agilent 1260II.

[0403] The GC-MS determination was performed using an Agilent 5977B ion source: EI source.

[0404] Chiral HPLC analysis was performed using a Shimadzu LC-20AT and a Thermo UltiMate 3000.

[0405] Preparative liquid chromatography was performed using SHIMADZU RFC-40 or LH-40. Chiral chromatography was performed using Waters UPCC analytical SFC.

[0406] The known starting materials disclosed herein can be synthesized using or according to methods known in the art, or are commercially available.

[0407] Example of intermediate preparation: Synthesis of intermediate A

[0408] Step 1: Synthesis of compound A-2

[0409] Pyridine-2(1H)-one (1.0 g, 10.52 mmol), trans-4-((tert-butoxycarbonyl)amino)cyclohexyl4-methylbenzenesulfonate (2.0 g, 5.26 mmol), cesium carbonate (5.40 g, 16.57 mmol), 4-dimethylaminopyridine (50 mg, 0.41 mmol), potassium iodide (50 mg, 0.301 mmol), and tetrahydrofuran (60 mL) were sequentially added to a reaction flask. The reaction was carried out at 90℃ for 16 h; LC-MS analysis showed the reaction was complete. The mixture was then cooled to room temperature, and 100 mL of ethyl acetate was added to the reaction system. The mixture was filtered, and the ethyl acetate phase was washed with 50 mL of water. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0%–75%, v / v) to give a yellow solid (compound A-2, 300 mg, yield: 19.52%). LC-MS m / z (ESI): 293.40 [M+H] + .

[0410] Step 2: Synthesis of compound A-3

[0411] Compound A-2 (300 mg, 1.03 mmol) was added to a reaction flask, followed by a 1,4-dioxane solution of hydrogen chloride (4 mol / L, 15 mL). The mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated to give a yellow solid (compound A-3, 275 mg, 100% yield), which was used directly in the next reaction. LC-MS m / z (ESI): 193.20 [M+H] + .

[0412] Step 3: Synthesis of intermediate A

[0413] Compound A-3 (275 mg, 1.03 mmol, calculated based on a 100% yield from the previous step), potassium carbonate (580 mg, 4.25 mmol), and N,N-dimethylformamide (4 mL) were added to the reaction flask. The mixture was stirred thoroughly, and chloroacetyl chloride (240 mg, 2.13 mmol) was added dropwise. The reaction was carried out at room temperature for 3 hours. After the reaction was complete, the mixture was quenched with water and extracted with a dichloromethane / methanol mixture (v / v = 10:1, 25 mL x 4). The organic phases were combined, concentrated under reduced pressure, and the residue was used directly in the next reaction step. LC-MS m / z (ESI): 269.40 [M+H] + .

[0414] Example 1. Synthesis of Compound 1

[0415] Step 1: Synthesis of compounds 1-3

[0416] 3-Chloro-5-(4-methylbenzene)-triazine (compound 1-1, commercially available, 1 g, 4.86 mmol), ethylene glycol dimethyl ether (14 mL), triethylamine (0.74 g, 7.31 mmol), and 2,5-diazabicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester (compound 1-2, commercially available, 1.19 g, 5.60 mmol) were added sequentially to the reaction flask. The reaction system was kept at 20-30 °C and stirred overnight. LC-MS was used to confirm complete reaction of the starting materials, and the next step was performed directly. LC-MS m / z (ESI): 382.50 [M+H] + .

[0417] Step 2: Synthesis of compounds 1-4

[0418] At room temperature, hydrochloric acid aqueous solution (3 mol / L, 11 mL) was added dropwise to the above reaction system. After the addition was complete, the temperature was raised to 55-60℃ and stirred for 5 h. LC-MS was used to confirm the complete reaction of the starting materials. The reaction solution was then cooled to 0-5℃, and a large amount of solid precipitated. The mixture was kept at 0-5℃ and stirred for 30 min. The mixture was then filtered, and the filter cake was dried under vacuum to obtain a yellow solid (compounds 1-4, 0.956 g, two-step yield 70.3%). LC-MS m / z (ESI): 282.30 [M+H] + .

[0419] Step 3: Synthesis of Compound 1

[0420] Add potassium carbonate (0.49 g, 3.54 mmol) and water (5 mL) to bottle 1, and cool to 20-30°C for later use. Add compounds 1-4 (0.36 g, 1.28 mmol) and tetrahydrofuran (5 mL) to bottle 2. Keep the temperature below 30°C, and add the potassium carbonate aqueous solution from bottle 1 dropwise to the system in bottle 2. After the addition is complete, stir to obtain a clear liquid. Compounds 1-5 (preparation method see Example 15, 0.25 g, 1.07 mmol) were added to the system. After the addition was complete, the system was heated to an internal temperature of 45-50 °C and stirred for 20 h. LCMS was used to detect that N-[(1r,4r)-4-acetamidocyclohexyl]-2-chloroacetamide had reacted completely. The reaction solution was concentrated under reduced pressure. Dichloromethane (30 mL) and water (20 mL) were added to the residue. After stirring, the mixture was allowed to stand for separation and liquid-liquid separation. The organic phase was concentrated, and the residue was purified by preparative chromatography (equipment: SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%-70% acetonitrile, flow rate: 75 mL / min) to obtain a yellow solid (compound 1, 100 mg, yield 16.7%). 1 H NMR (400MHz, DMSO-d6): δ9.22(d,J=6.6Hz,1H),8.15(s,2H),7.70(d,J=7.8Hz,1H), 7.51(d,J=8.4Hz,1H),7.38(d,J=7.8Hz,2H),4.84(d,J=60.2Hz,1H),3.97(s,1H),3. 73-3.39(m,3H),3.17(dd,J=31.9,15.5Hz,2H),2.99(s,3H),2.40(s,3H),2.19-2.03 (m,1H),1.88(m,2H),1.82-1.58(m,8H),1.41-1.26(m,2H),1.26-1.15(m,2H).LC-MS m / z(ESI):478.60[M+H] +.

[0421] Examples 2-14 were prepared according to the method of Example 1, and the compounds shown in Table 1 below were obtained.

[0422] Table 1:

[0423] The compounds obtained in Examples 2-14 1 H NMR and MS are shown in Table 2.

[0424] Table 2:

[0425] Example 15. Synthesis of Compound 15

[0426] Step 1: Synthesis of compounds 1-5

[0427] Trans-2-(4-aminocyclohexyl)acetamide hydrochloride (compound 15-1, commercially available, 10.00 g, 51.9 mmol) and potassium carbonate (21.52 g, 155.7 mmol) were added sequentially to a reaction flask, followed by N,N-dimethylformamide (100 mL). The mixture was stirred to obtain a turbid solution. Chloroacetyl chloride (8.79 g, 77.9 mmol) was weighed and added dropwise to the system. The system temperature was controlled at 10–25 °C using an ice-water bath. After the addition was complete, the mixture was allowed to return to room temperature naturally, and the reaction was allowed to proceed for 16 h. LC-MS analysis confirmed the reaction was complete. Hydrochloric acid (4 mol / L, 70 mL) was then slowly added dropwise to the turbid reaction solution, producing a large number of bubbles. After the addition was complete, saturated sodium chloride solution (140 mL) was added dropwise to the system, which remained turbid. The mixture was filtered, and the filter cake was washed with water (100 mL) and then with n-heptane (30 mL). The filter cake was vacuum dried (50°C) to obtain an off-white solid (compounds 1-5, 5.864 g, yield 48.56%). 1 H NMR (400MHz, DMSO-d6): δ8.09(d,J=7.7Hz,1H),7.71(d,J=7.7Hz,1H),3.99(s,2H),3.47(m,2H),1.86-1.67(m,7H),1.35-1.09(m,4H).LC-MS m / z(ESI):233.20[M+H] + .

[0428] Step 2: Synthesis of Compound 15-4

[0429] Compounds 1-5 (300 mg, 1.85 mmol), N-Boc-piperazine (431 mg, 1.61 mmol), and dimethyl sulfoxide (3 mL) were added sequentially to a reaction flask. Under stirring, diisopropylethylamine (416 mg, 3.22 mmol) was added, and the mixture was heated to 60 °C and reacted for 16 h. After LC-MS analysis confirmed the reaction was complete, water (30 mL) was added to the reaction solution, resulting in the precipitation of a solid. The solid was filtered, and the filter cake was collected and dried under reduced pressure to obtain a pale yellow solid (compound 15-4, 129 mg, yield: 14.47%). The filtrate was purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a white solid (compound 15-4, 485 mg, yield: 54.80%), which was combined with the previously obtained pale yellow solid. LC-MS m / z (ESI): 383.60 [M+H] + .

[0430] Step 3: Synthesis of Compound 15-5

[0431] Compound 15-4 (129 mg, 0.34 mmol) was added to a reaction flask, followed by a 1,4-dioxane solution of hydrogen chloride (4 mL, 4 mol / L, 16 mmol). The reaction was carried out under nitrogen protection at room temperature for 16 h. LC-MS analysis confirmed the complete reaction of the starting material and the formation of the product. The reaction solution was concentrated under reduced pressure to give a white solid (compound 15-5, 120 mg, 100% yield). The crude product was used directly in the next step. LC-MS m / z (ESI): 283.30 [M+H] + .

[0432] Step 4: Synthesis of Compounds 15-7

[0433] Compound 15-6 (0.8 g, 5 mmol), selenium dioxide (1.0 g, 9 mmol), water (0.12 mL), and 1,4-dioxane (5 mL) were added sequentially to a reaction flask and stirred at 80 °C for 10 h. The reaction mixture was analyzed by LC-MS to confirm the reaction was complete. The reaction solution was filtered, and the filtrate was collected and concentrated to dryness under reduced pressure. Water (5 mL) was added to the concentrate, and the mixture was stirred at 100 °C for 2 h. The mixture was then cooled to room temperature and stirred for 1 h. The mixture was filtered, and the filter cake was washed with water (15 mL). The wet filter cake was used directly for the next reaction step. LC-MS m / z (ESI): 175.20 [M+H] + .

[0434] Step 5: Synthesis of Compounds 15-8

[0435] The wet sample of compound 15-7 was added to water (5 mL) and stirred at 60 °C for 20 min. Then, an aqueous solution of aminourea hydrochloride (0.83 g, 7.5 mmol) (6 mL) was added, and the mixture was stirred at 60 °C for 16 h. The reaction was confirmed by LC-MS. The mixture was filtered, and the filter cake was washed with water (15 mL). The wet filter cake was reserved for later use. LC-MS m / z (ESI): 270.20 [M+K] + 230.20 [MH] - .

[0436] Step 6: Synthesis of Compounds 15-9

[0437] The wet product of compound 15-8 was added to water (20 mL), followed by sodium carbonate (0.95 g, 9 mmol). The mixture was stirred at 100 °C for 3 h. LC-MS analysis confirmed the reaction was complete. The mixture was filtered, and the filter cake was washed with water (40 mL). After drying, the filter cake was added to tetrahydrofuran (20 mL) and stirred. Anhydrous sodium sulfate was added and the mixture was dried. The solution was concentrated under reduced pressure to give a yellow solid (compound 15-9, 396 mg, three-step yield: 37.2%). LC-MS m / z (ESI): 214.10 [M+H] + .

[0438] Step 7: Synthesis of Compounds 15-10

[0439] Compound 15-9 (396 mg, 1.86 mmol) was dissolved in DME (5 mL), DMF (0.05 mL) was added, the mixture was heated to 75 °C, thionyl chloride (333 mg, 2.8 mmol) was added, and the mixture was stirred at 75 °C for 4 h. The reaction was detected by LCMS after completion. The reaction solution was concentrated to dryness under reduced pressure, and purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a yellow solid (compound 15-10, 90 mg, yield: 22.7%). 1 H NMR (400MHz, CDCl3): δ9.61(s,1H),8.12(d,J=8.5Hz,2H),7.27(d,J=8.4Hz,2H),2.08-1.98(m,1H),1.19-1.13(m,2H),0.90-0.83(m,2H).LC-MS m / z(ESI):232.10[M+H] + .

[0440] Step 8: Synthesis of Compound 15

[0441] Compound 15-10 (10 mg, 0.043 mmol), compound 15-5 (21 mg, 0.066 mmol), and triethylamine (18 mg, 0.172 mmol) were added to DME (10 mL) and stirred at 25 °C for 20 h. The reaction mixture was analyzed by LCMS to confirm the reaction was complete. The reaction solution was then purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a yellow solid (compound 15, 12 mg, yield: 60%). 1 H NMR (400MHz, DMSO-d6): δ9.26 (s, 1H), 8.13 (d, 2H), 7.71 (d, J = 7.7Hz, 1H), 7. 60(d,J=8.3Hz,1H),7.25(d,2H),3.92(t,J=4.9Hz,4H),3.59-3.42(m,2H),2. 97(s,2H),2.56(t,J=5.0Hz,4H),2.07-1.98(m,1H),1.84-1.72(m,7H),1.35 -1.27(m,2H),1.25-1.18(m,2H),1.10-0.99(m,2H),0.83-0.72(m,2H).LC-MS m / z (ESI): 478.60 [M+H] + .

[0442] Examples 16–18 were prepared according to the method of Example 15, and the resulting compounds are shown in Table 3.

[0443] Table 3:

[0444] The compounds obtained in Examples 16-17 1 H NMR and MS are shown in Table 4.

[0445] Table 4:

[0446] Example 19. Synthesis of Compound 19

[0447] Step 1: Synthesis of Compound 19-3

[0448] N-benzyl-bis(o-chloroethyl)amino hydrochloride (compound 19-1, commercially available, 1.0 g, 3.72 mmol), 1-aminocyclopropane-1-carboxylic acid ethyl ester hydrochloride (compound 19-2, commercially available, 629 mg, 3.80 mmol), sodium bicarbonate (1.56 g, 18.61 mmol), and potassium iodide (62 mg, 0.37 mmol) were added sequentially to a reaction flask. Anhydrous ethanol (30 mL) was added, and the mixture was heated to reflux under nitrogen protection. The reaction mixture was checked by LC-MS to confirm complete reaction. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product (1.22 g). The crude product was purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10μm 250*50mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a white solid (compound 19-3, 0.74 g, yield 68.92%). LC-MS m / z (ESI): 289.40 [M+H] + .

[0449] Step 2: Synthesis of Compound 19-4

[0450] Compound 19-3 (0.73 g, 2.53 mmol) was dissolved in methanol (30 mL) and transferred to a hydrogenation reactor. 10% palladium on carbon wet powder (0.10 g) was added, and the reactor was sealed. The mixture was purged with nitrogen three times, followed by hydrogen purging three times. The hydrogen pressure was increased to 2.4 MPa, and the temperature was raised to 40 °C for 2 h. LC-MS analysis confirmed complete reaction of the starting material. The reaction solution was cooled to room temperature, purged with nitrogen, and filtered. The filtrate was concentrated under reduced pressure to obtain a solid, which was dissolved in tetrahydrofuran (5 mL). Crystallization was precipitated by adding n-heptane (50 mL), filtered, and the filter cake was dried under vacuum at 45 °C to obtain a white solid (compound 19-4, 323 mg, yield 64.36%). LC-MS m / z (ESI): 199.20 [M+H] + .

[0451] Step 3: Synthesis of Compound 19-5

[0452] Compound 19-4 (188 mg, 0.95 mmol) was added to a reaction flask, followed by methanol (2 mL) and dichloromethane (2 mL). Triethylamine (144 mg, 1.42 mmol) was added with stirring under nitrogen protection. 3-Chloro-5-(4-Tolyl)-triazine (compound 1-1, 254 mg, 1.24 mmol) was dissolved in N-methylpyrrolidone (1 mL) and added dropwise to the above system at room temperature. After addition, the reaction was allowed to proceed at room temperature for 16 h, and LC-MS was used to confirm complete reaction of the starting material. The reaction solution was concentrated under reduced pressure at 40 °C. The residue was dissolved in ethyl acetate (30 mL) and water (30 mL) with stirring, allowed to stand for separation, and then separated. The organic phase was concentrated under reduced pressure to obtain a crude oily product (0.75 g). The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 10%–35%, v / v) to give a yellow solid (compound 19-5, 157 mg, yield: 45.06%). LC-MS m / z (ESI): 368.40 [M+H] + .

[0453] Step 4: Synthesis of Compound 19-6

[0454] Compound 19-5 (157 mg, 0.43 mmol) was dissolved in tetrahydrofuran (5 mL), methanol (5 mL) was added, followed by a solution of sodium hydroxide (500 mg, 12.5 mmol) in water (5 mL). The mixture was heated to 40 °C and reacted for 16 h. TLC showed that the reaction was complete (evolving solvent: n-heptane / ethyl acetate = 1:1, v / v, Rf starting material = 0.5, Rf product = 0.15). The reaction solution was concentrated under reduced pressure, and the residue was adjusted to pH = 6 with hydrochloric acid (2 mol / L). A solid precipitated out. The solid was filtered, the filter cake was washed with water, and dried under vacuum at 50 °C to give a yellow solid (compound 19-6, 119 mg, yield 82.06%). LC-MS m / z (ESI): 340.30 [M+H] + .

[0455] Step 5: Synthesis of Compound 19

[0456] Compound 19-6 (30 mg, 0.088 mmol), N-(trans-4-aminocyclohexyl)acetamide hydrochloride (compound 19-7, commercially available, 22 mg, 0.115 mmol), and diisopropylethylamine (69 mg, 0.53 mg) were added sequentially to a reaction flask. N,N-dimethylformamide (5 mL) was added, and 1-propylphosphonic anhydride (50% ethyl acetate solution, 84 mg, 0.133 mmol) was added dropwise with stirring. The reaction was carried out at room temperature for 16 h. LC-MS showed that a product was formed and the remaining raw materials were removed. The reaction solution was quenched with sodium bicarbonate solution (50 mL), extracted with ethyl acetate (15 mL × 3), and the ethyl acetate phases were combined, washed with saturated sodium chloride solution (15 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10μm 250*50mm ID; mobile phase A: 10mM ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80mL / min; wavelength: 210 / 254nm) to give a yellow solid (compound 19, 3.3mg, yield: 7.82%). 1 H NMR (400MHz, DMSO-d6): δ9.27(s,1H),8.15(d,J=8.2Hz,2H),7.73(m,2H),7.38(d,J=8.0Hz,2H),3.95(m,4H),3.63-3. 41(m,2H),2.55(m,4H),2.40(s,3H),1.79-1.76(m,7H),1.48-1.30(m,2H),1.28-1.14(m,2H),1.04-0.86(m,4H).LC-MS m / z(ESI):478.60[M+H] + .

[0457] Example 20. Synthesis of Compound 20

[0458] Step 1: Synthesis of Compound 20-2

[0459] 4,5-Dichloropyridazine-3(2H)-one (compound 20-1, commercially available, 10.0 g, 60 mol) was dissolved in N,N-dimethylformamide (30 mL), followed by the addition of potassium carbonate (9.4 g, 68 mmol) and benzyl bromide (11.0 g, 66 mmol). The mixture was stirred at room temperature for 16 hours under nitrogen protection. The reaction solution was then poured directly into water (100 mL), stirred for 15 minutes, filtered, and dried under vacuum at 40 °C for 3 hours to give a gray solid (compound 20-2, 14.2 g, yield: 92.8%). LC-MS m / z (ESI): 255.10 [M+H] + .

[0460] Step 2: Synthesis of Compound 20-3

[0461] Compound 20-2 (2.0 g, 7.84 mmol) was dissolved in 1,4-dioxane (40 mL), and a 30% sodium methoxide methanol solution (1.54 g, 8.55 mmol) was added. The reaction was carried out at room temperature for 3 h. Water (50 mL) and dichloromethane (50 mL) were added, and the mixture was separated. The aqueous phase was extracted with dichloromethane (50 mL × 2). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to give a pale yellow oil, which was used directly in the next step. LC-MS m / z (ESI): 251.20 [M+H] + .

[0462] Step 3: Synthesis of Compound 20-4

[0463] Compound 20-3 (7.84 mmol), p-toluenepinacol boronic acid ester (2.05 g, 9.41 mmol), and sodium carbonate (3.32 g, 31.36 mmol) were dissolved in toluene (30 mL). An aqueous solution of sodium carbonate (3.32 g, 31.36 mmol) (16 mL) was added, followed by the addition of tetrakis(triphenylphosphine)palladium (0.23 g, 0.196 mmol). The mixture was heated to 100 °C and stirred for 16 hours. After cooling to room temperature, dichloromethane (50 mL) was added and the mixture was separated. The aqueous phase was extracted with dichloromethane (30 mL × 2). The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0–30%, v / v) to give a colorless oil (compound 20-4, 0.7 g, yield: 29.1%). 1 H NMR (400MHz, DMSO-d6): δ8.02(s,1H),7.54-7.48(m,2H),7.38(m,4H),7.32(m,3H),5.31(s,2H),4.00(s,3H),2.37(s,3H).LC-MS m / z(ESI):307.30[M+H]+ .

[0464] Step 4: Synthesis of compound 20-5

[0465] Compound 20-4 (0.7 g, 2.28 mmol) was dissolved in phosphorus oxychloride (5 mL), heated to 120 °C, and reacted for 20 hours. The mixture was then cooled to room temperature, and phosphorus oxychloride (3 mL) was added. The temperature was raised to 120 °C, and the reaction was continued for 5 hours. The mixture was concentrated to dryness under pressure, and ice water (20 mL) was slowly added. Dichloromethane (30 mL) was added, and the mixture was separated. The aqueous phase was extracted with dichloromethane (20 mL × 2). The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0–20%, v / v) to give an off-white solid (0.12 g, yield: 22.0%). LC-MS m / z (ESI): 239.10 [M+H] + .

[0466] Step 5: Synthesis of compound 20-6

[0467] Compound 20-5 (0.12 g, 0.502 mmol) was dissolved in ethylene glycol dimethyl ether (5 mL), followed by the addition of N-Boc-piperazine (103 mg, 0.552 mmol) and triethylamine (76 mg, 0.753 mmol). The mixture was heated to 85 °C under nitrogen protection and stirred for 16 hours. After cooling to room temperature, the reaction solution was concentrated under reduced pressure. The residue was used directly in the next step. LC-MS m / z (ESI): 389.40 [M+H] + .

[0468] Step 6: Synthesis of compound 20-7

[0469] Compound 20-6 (0.502 mmol) was dissolved in trifluoroacetic acid (2 mL) and reacted at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was used directly in the next reaction. LC-MS m / z (ESI): 289.30 [M+H] + .

[0470] Step 7: Synthesis of Compound 20

[0471] Compound 20-7 (0.502 mmol) was dissolved in dimethyl sulfoxide (4 mL), and then compounds 1-5 (120 mg, 0.502 mmol) and diisopropylethylamine (260 mg, 2.01 mmol) were added sequentially. The mixture was heated to 60 °C under nitrogen protection and stirred for 4 hours. After cooling to room temperature, the mixture was purified by preparative chromatography (SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 15%-70% acetonitrile, flow rate: 75 mL / min) to obtain an off-white powder (compound 20, 39 mg, three-step yield: 16.0%). 1 H NMR (400MHz, DMSO-d6): δ8.80(s,1H),7.71(d,J=7.8Hz,1H),7.60(d,J=8.3Hz,1H),7.51-7.41(m,2H),7.35(d,J=7.9Hz,2H),3. 63-3.47(m,2H),3.47-3.41(m,4H),2.99(s,2H),2.64(t,J=4.8Hz,4H),2.38(s,3H),1.80-1.74(m,7H),1.43-1.11(m,4H).LC-MS m / z(ESI):485.50[M+H] + .

[0472] Example 21. Synthesis of Compound 21

[0473] Step 1: Synthesis of Compound 21-2

[0474] At room temperature, 2-(1-(tert-butyloxycarbonyl)-4-hydroxypiperidin-4-yl)acetic acid (compound 21-1, commercially available, 1.3 g, 5.01 mmol), DMF (26 mL), DIPEA (3.24 g, 25.05 mmol), N-(trans-4-aminocyclohexyl)acetamide hydrochloride (compound 19-7, 1.06 g, 5.511 mmol), and HBTU (3.8 g, 10.02 mmol) were added sequentially to a reaction flask. The system was kept at 20-30 °C and stirred for 20 h. LC-MS showed no residual starting material. The reaction solution was purified by silica gel column chromatography (eluent: DCM / MeOH = 99:1 to 92:8, v / v) to give a yellow solid (compound 21-2, 500 mg, yield: 25.1%). LC-MS m / z (ESI): 396.40 [MH] - .

[0475] Step 2: Synthesis of compound 21-3

[0476] At room temperature, compound 21-2 (140 mg, 0.35 mmol), methanol (7 mL), and a 1,4-dioxane solution of hydrogen chloride (4 mol / L, 2 mL) were added sequentially to a reaction flask. The mixture was heated to 40 °C and stirred for 3 h. LC-MS analysis showed no residual starting material. The reaction solution was concentrated under reduced pressure to give a yellow solid (compound 21-3, 122 mg, yield 99%). LC-MS m / z (ESI): 298.40 [M+H] + .

[0477] Step 3: Synthesis of Compound 21

[0478] At room temperature, compound 21-3 (117 mg, 0.39 mmol), DCM (3.3 mL), MeOH (0.7 mL), TEA (88 mg, 0.98 mmol), and 3-chloro-5-(p-tolyl)-1,2,4-triazine (compound 1-1, 60 mg, 0.29 mmol) were added sequentially to the reaction flask. The system was stirred at 20-25 °C for 20 h. After the reaction was complete as determined by LC-MS, the reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (eluent: DCM / MeOH = 99:1 to 93:7, v / v) to obtain a yellow solid crude product. The crude product was purified by preparative chromatography (instrument: SHIMADZU RFC-40, column: Kromasil ET C18 10μm 250*50mm ID, mobile phase A: 10mM ammonium formate; mobile phase B: acetonitrile; gradient: 10%-70% acetonitrile, flow rate: 75mL / min) to obtain a yellow powder (compound 21, 66.5mg, yield 36.4%). 1 H NMR (400MHz, DMSO-d6): δ9.21(s,1H),8.13(d,J=8.2Hz,2H),7.84(d,J=7.8Hz,1H),7.68(d,J=7.7Hz,1H),7.37(d,J=8.0Hz,2H),5.03(s, 1H),4.46(d,J=13.3Hz,2H),3.52-3.37(m,4H),2.39(s,3H),2.25(s,2H),1.77-1.75(m,7H),1.67-1.53(m,4H),1.26-1.08(m,4H).LC-MS m / z(ESI):467.50[M+H] +

[0479] Example 22. Synthesis of Compound 22

[0480] Compound 21 (600 mg, 1.29 mmol) and THF (150 mL) were added to the reaction flask. After purging with nitrogen three times, the reaction solution was cooled to -70 to -80 °C, and DAST (7.7 g, 48 mmol) was added dropwise. After the addition was complete, the system was kept at -70 to -80 °C and stirred for 1-2 h, and then heated to 25-30 °C and stirred for 20 h. The reaction of the starting materials was confirmed to be complete by LC-MS, and the reaction solution was concentrated under reduced pressure. Dichloromethane (300 mL) and purified water (200 mL) were added to the residue, and the pH was adjusted to 7-8 with saturated sodium bicarbonate. The organic phase was separated and washed with purified water (200 mL × 5). The organic phase was concentrated under reduced pressure, and the residue was sent for preparative chromatography for purification (SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 15%-70% acetonitrile, flow rate: 75 mL / min), yielding a yellow powder (compound 22, 33.6 mg, yield 5.5%). 1 H NMR (400MHz, DMSO-d6): δ9.27 (s, 1H), 8.16 (d, J = 8.4Hz, 2H), 7.85 (d, J = 7.8 Hz,1H),7.69(d,J=7.8Hz,1H),7.39(d,J=8.0Hz,2H),4.63(d,J=13.3Hz,2H) ,3.45(s,2H),3.37-3.34(m,1H),3.31-3.26(m,1H),2.47(s,1H),2.40(s,3H ),1.95(q,J=12.0,10.6Hz,3H),1.88-1.65(m,9H),1.24-1.10(m,4H).LC-MS m / z (ESI): 469.60 [M+H] + .

[0481] Example 23. Synthesis of Compound 23

[0482] Step 1: Synthesis of Compound 23-2

[0483] 3-Chloro-5-(p-Tolyl)-1,2,4-triazine (compound 1-1, 1.00 g, 4.86 mmol) was dissolved in toluene (10 mL) and water (1 mL). 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborane-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (compound 23-1, commercially available, 1.80 g, 5.836 mmol) was added, followed by cesium carbonate (4.70 g, 14.59 mmol) and XPhos Pd G3 (560 mg, 0.49 mmol). The mixture was reacted under nitrogen protection at 100 °C for 16 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0–45%, v / v) to give a yellow solid (compound 23-2, 1.01 g, yield 59.1%). LC-MS m / z (ESI): 353.40 [M+H] + .

[0484] Step 2: Synthesis of Compound 23-3

[0485] Compound 23-2 (300 mg, 0.849 mmol) was dissolved in methanol (3 mL), and a solution of 1,4-dioxane in hydrogen chloride (4 mol / L, 1 mL) was added. The mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to obtain the residue (compound 23-3, 321 mg, 100% yield), which was used directly in the next step.

[0486] Step 3: Synthesis of Compound 23

[0487] Compound 23-3 (321 mg, 1.27 mmol) was dissolved in thionyl chloride (5 mL) and N,N-diisopropylethylamine (657 mg, 5.08 mmol), and compound 1-5 (296 mg, 1.27 mmol) was added. After stirring at 60 °C for 16 hours, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative separation (instrument: SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 25%-85% acetonitrile, flow rate: 75 mL / min), yielding a white solid (compound 23, 14 mg, yield: 2.45%). 1H NMR (400MHz, DMSO-d6): δ9.88(s,1H),8.36-8.23(m,2H),7.69(d,J=7.8Hz,1H),7.56(d,J=8.3Hz,1H),7.50-7.35(m,3H),3.57 -3.43(m,2H),3.34(d,J=3.3Hz,2H),3.07(s,2H),2.77-2.72(m,2H),2.41(s,3H),1.77-1.75(m,7H),1.36-1.15(m,6H).LC-MS m / z(ESI):449.50[M+H] + .

[0488] Example 24. Synthesis of Compound 24

[0489] Step 1: Synthesis of Compound 24-1

[0490] Compound 23-2 (300 mg, 0.85 mmol) was dissolved in dimethyl sulfoxide (5 mL), and added dropwise to a solution of trimethyl iodide sulfoxide (337 mg, 1.53 mmol) and potassium tert-butoxide (172 mg, 1.53 mmol) in dimethyl sulfoxide (5 mL). The mixture was stirred at room temperature for 16 hours. The mixture was quenched with saturated brine (10 mL) and saturated ammonium chloride (10 mL), and extracted with ethyl acetate (20 mL). The organic phase was washed twice with water (20 mL × 2) and twice with saturated brine (20 mL × 2). The mixture was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0–45%, v / v) to give a pale yellow solid (compound 24-1, 154 mg, yield 49.5%). LC-MS m / z (ESI): 367.40 [M+H] + .

[0491] Step 2: Synthesis of Compound 24-2

[0492] Compound 24-1 (154 mg, 0.42 mmol) was dissolved in methanol (5 mL), and a solution of 1,4-dioxane in hydrogen chloride (4 mol / L, 1 mL) was added. The mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to give the residue (compound 24-2, 68 mg, yield 60.75%), which was used directly in the next step.

[0493] Step 3: Synthesis of Compound 24

[0494] Compound 24-2 (68 mg, 0.26 mmol) was dissolved in a mixture of dimethyl sulfoxide (3 mL) and N,N-diisopropylethylamine (132 mg, 1.021 mmol), and compound 1-5 (59 mg, 0.26 mmol) was added. The system was heated to 60 °C and stirred for 16 hours. After cooling to room temperature, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative chromatography (instrument: SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 15%-70% acetonitrile, flow rate: 75 mL / min) to give a yellow solid (compound 24, 10.7 mg, yield 9.1%). 1 H NMR (400MHz, DMSO-d6): δ9.79 (s, 1H), 8.28-8.14 (m, 2H), 7.69 (d, J = 7.8Hz, 1H), 7.39 ( d,J=8.1Hz,3H),3.60-3.41(m,2H),3.24-3.20(m,2H),2.85(d,J=9.3Hz,3H),2.69(dd, J=11.3,5.1Hz,1H),2.38(s,3H),2.16(dq,J=14.4,4.8Hz,1H),2.02(ddt,J=29.2,10. 3,5.4Hz,2H),1.77-1.70(m,7H),1.52(dd,J=9.3,3.3Hz,1H),1.39-1.14(m,5H).LC-MS m / z(ESI): 463.60[M+H] + .

[0495] Example 25. Synthesis of Compound 25

[0496] Step 1: Synthesis of Compound 25-2

[0497] 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine (compound 25-1, commercially available, 300 mg, 1.56 mmol) and potassium carbonate (647 mg, 4.68 mmol) were added to a reaction flask, followed by N,N-dimethylformamide (5 mL), and then chloroacetyl chloride (265 mg, 2.34 mmol). The mixture was stirred at room temperature for 1 hour under nitrogen protection. After cooling to room temperature, water (30 mL) and dichloromethane (30 mL) were added. The mixture was separated, and the aqueous phase was extracted with dichloromethane (30 mL × 2). The organic phase was washed with saturated brine (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and used directly in the next step. LC-MS m / z (ESI): 269.20 [M+H] + .

[0498] Step 2: Synthesis of Compound 25

[0499] Compound 25-2 (1.56 mmol) was dissolved in dimethyl sulfoxide (5 mL), and compound 25-3 (455 mg, 1.56 mmol) and diisopropylethylamine (605 mg, 4.68 mmol) were added sequentially. Under nitrogen protection, the mixture was heated to 60 °C and stirred for 3 hours. After cooling to room temperature, the mixture was purified by preparative separation (instrument: SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 20%-95% acetonitrile, flow rate: 75 mL / min) to give a yellow solid (compound 25, 180 mg, two-step yield: 23.7%). 1 H NMR (400MHz, DMSO-d6): δ9.29 (s, 1H), 8.16 (d, J = 8.1Hz, 2H), 7.39 (d, J = 8.0Hz, 2H), 4.98 (d, J = 98. 7Hz,2H),4.43-4.06(m,4H),3.98-3.79(m,4H),3.42(s,2H),2.63-2.58(m,4H),2.41(s,3H).LC-MS m / z(ESI):488.50[M+H] + .

[0500] Example 26. Synthesis of Compound 26

[0501] Step 1: Synthesis of Compound 26-2

[0502] (4-Bromophenyl)pentafluorothione (compound 26-1, 2.4 g, 9.89 mmol), tributyl(1-ethoxyvinyl)stanane (4.30 mg, 11.87 mmol), Pd(dppf)Cl2 (0.36 g, 0.50 mmol), TEA (1.40 g, 13.85 mmol), and 1,4-dioxane (50 mL) were added sequentially to a reaction flask, purged with nitrogen three times, and the mixture was heated to 80–85 °C and stirred for 5 hours. After the reaction was completed by GCMS, the reaction solution was cooled to room temperature, and 20 mL of hydrochloric acid aqueous solution (2 mol / L) was added dropwise. The mixture was stirred at room temperature for 2 hours, and KF (2.5 g, 43.03 mmol) was added. The mixture was stirred for another hour and then filtered (with diatomaceous earth as a filter). The filtrate was extracted twice with ethyl acetate (25 mL × 2) to separate the organic phase. The organic phase was washed once with saturated brine (25 mL) and separated again. The mixture was concentrated under reduced pressure, and the residue was purified by preparative chromatography (SHIMADZU RFC-40, column: Kromasil ET C18 10 μm 250*50 mm ID, mobile phase: aqueous phase (10 mmol / L ammonium formate) and acetonitrile, gradient ratio: acetonitrile 15%-70%, flow rate: 75 mL / min) to give a yellow solid (compound 26-2, 1.42 g, yield 58.5%). 1 H NMR (400MHz, Chloroform-d): δ8.08-7.98 (d, 2H), 7.87 (d, J = 8.8Hz, 2H), 2.65 (s, 3H). GC-MS m / z(EI): 246.10[M] + .

[0503] Step 2: Synthesis of Compound 26-3

[0504] Compound 26-2 (400 mg, 1.6 mmol), selenium dioxide (325 mg, 2.9 mmol), water (0.06 mL), and 1,4-dioxane (2.5 mL) were added sequentially to a reaction flask, and the mixture was heated to 80 °C and stirred overnight. The reaction proceeds were monitored by LC-MS until complete. The reaction solution was filtered, and the filter cake was washed with tetrahydrofuran (15 mL). The filtrate was collected, concentrated under reduced pressure, and the residue was used directly in the next reaction step. LC-MS m / z (ESI): 277.20 [MH] - .

[0505] Step 3: Synthesis of Compound 26-4

[0506] Add 4 mL of water to compound 26-3 obtained in the previous step, heat to 60 °C and stir for 20 min. Then add an aqueous solution of aminourea hydrochloride (270 mg, 2.4 mmol) (dissolved in 2 mL of water), and continue stirring at 60 °C for 1 h. LC-MS analysis showed the reaction was complete. Filter, wash the filter cake with 5 mL of water, and use the wet filter cake directly for the next reaction. LC-MS m / z (ESI): 318.20 [M+H] + .

[0507] Step 4: Synthesis of compound 26-5

[0508] Water (5 mL) and 1,4-dioxane (2 mL) were added to the wet sample of compound 26-4, followed by sodium carbonate (254 mg, 2.4 mmol). The mixture was heated to 100 °C and stirred for 1 h. The reaction was confirmed by LCMS. The reaction solution was purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain 60 mg of yellow solid (compound 26-5, three-step yield: 12.3%). 1 H NMR (400MHz, DMSO-d6): δ13.53 (s, 1H), 8.78 (s, 1H), 8.40 (d, J = 8.6Hz, 2H), 8.18-8.06 (m, 2H). LC-MS m / z (ESI): 300.20 [M+H] + .

[0509] Step 5: Synthesis of compound 26-6

[0510] Compound 26-5 (60 mg, 0.20 mmol) was dissolved in DME (5 mL), DMF (0.05 mL) was added, the mixture was heated to 75 °C, thionyl chloride (60 mg, 0.5 mmol) was added, and the mixture was stirred at 75 °C for 4 h. The reaction was detected by LCMS to indicate completion, the reaction solution was concentrated under reduced pressure, and the residue was used directly in the next step. 1 H NMR (400MHz, DMSO-d6): δ10.25 (s, 1H), 8.52 (d, J = 8.6Hz, 2H), 8.23-8.14 (m, 2H). LC-MS m / z (ESI): 318.10 [M+H] + .

[0511] Step 6: Synthesis of Compound 26

[0512] Compound 15-5 (90 mg, 0.25 mmol), triethylamine (96 mg, 0.95 mmol), and DMF (5 mL) were added to compound 26-6 (theoretical value 63.70 mg, 0.20 mmol), and the mixture was heated to 60 °C and stirred for 3 h. The reaction was confirmed by LC-MS. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a yellow solid (compound 26, 55 mg, yield: 51.67%). 1 H NMR (400MHz, DMSO-d6): δ9.40(s,1H),8.47(d,J=8.6Hz,2H),8.12(d,J=8.9Hz,2H),7.75(d,J=7.7Hz,1H),7.66(d,J=8.2Hz,1H),4.10-3.87(m, 4H),3.65-3.47(m,2H),3.01(s,2H),2.68-2.57(m,4H),1.88-1.71(m,7H),1.35(dd,J=23.8,10.9Hz,2H),1.23(dd,J=23.1,11.4Hz,2H).LC-MS m / z(ESI):564.60[M+H] + .

[0513] Example 27. Synthesis of Compound 27

[0514] The synthesis of compound 27 follows the preparation method described in Example 1.

[0515] 1 H NMR (400MHz, DMSO-d6): δ9.28(s,1H),8.21-8.11(m,2H),7.75(s,1H),7.69(d, J=8.3Hz,1H),7.45-7.30(m,3H),6.37(s,1H),6.28-5.92(m,1H),4.79-4.64(m, 1H),3.94(t,J=4.9Hz,4H),3.83-3.68(m,1H),3.00(s,2H),2.59(t,J=5.0Hz,4 H),2.40(s,3H),1.99-1.84(m,2H),1.84-1.69(m,4H),1.62-1.37(m,2H).LC-MS m / z (ESI): 488.40 [M+H] +.

[0516] Example 28. Synthesis of Compound 28

[0517] Step 1: Synthesis of Compound 28-3

[0518] 5.00 g (23.33 mmol) of trans-(4-aminocyclohexyl)carbamate tert-butyl ester was added to a reaction flask, followed by acetonitrile (50 mL) and diisopropylethylamine (4.82 g, 37.33 mmol). A turbid solution was obtained with stirring. Acrylic acid (3.53 g, 48.99 mmol) was weighed, diluted with acetonitrile (40 mL), and added dropwise to the above system. After addition was complete, the system was refluxed for 20 h. LC-MS analysis indicated that the reaction was complete. The system was cooled to room temperature, filtered, and the filter cake was washed with acetonitrile and dried under vacuum at 50 °C to obtain a pale yellow solid (compound 28-3, 5.40 g, 80.82%). LC-MS m / z (ESI): 287.30 [M+H] + .

[0519] Step 2: Synthesis of Compound 28-4

[0520] Compound 28-3 (500 mg, 1.75 mmol) was added to a reaction flask, followed by anhydrous acetonitrile (50 mL), and stirred to obtain a turbid solution. Sodium bicarbonate powder (7.33 g, 87.30 mmol) was added, followed by p-toluenesulfonyl chloride (3.33 g, 17.46 mmol). The reaction was carried out under nitrogen atmosphere and refluxed for 20 h. LC-MS analysis confirmed complete reaction of the reactants. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with acetonitrile. The filtrate was concentrated under reduced pressure to obtain a yellow solid, which was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm). ID; Mobile phase A: 10 mmol ammonium formate; Mobile phase B: acetonitrile; Gradient: 15%–95% acetonitrile; Flow rate: 80 mL / min; Wavelength: 210 / 254 nm), yielding a yellow solid (compound 28-4, 66 mg, yield: 14.09%).

[0521] LC-MS m / z (ESI): 291.20 [M+Na] + .

[0522] Step 3: Synthesis of Compound 28-5

[0523] Compound 28-4 (60 mg, 0.224 mmol) was added to a reaction flask, followed by anhydrous dichloromethane (10 mL). The mixture was stirred until dissolved, and then trifluoroacetic acid (0.60 g, 5.26 mmol) was added dropwise. The reaction was carried out at room temperature for 16 h under nitrogen protection. LCMS was used to determine when the reaction was complete. The reaction solution was concentrated under reduced pressure, and dichloromethane (10 mL × 2) was added to the concentrate, followed by another concentration under reduced pressure. The residue was used directly in the next reaction step.

[0524] LC-MS m / z (ESI): 169.20 [M+H] + .

[0525] Step 4: Synthesis of compound 28-6

[0526] Anhydrous dichloromethane (10 mL) and triethylamine (136 mg, 1.34 mmol) were added to compound 28-5 obtained in the previous step (yield of 100%, 0.224 mmol). The mixture was kept under nitrogen protection and cooled in an ice-water bath. A solution of chloroacetyl chloride (27 mg, 0.235 mmol) in dichloromethane (0.2 mL) was added dropwise. After the addition was complete, the mixture was allowed to return to room temperature and stirred for 2 h. The reaction mixture was checked by LCMS to confirm that the starting material had reacted completely. The reaction solution was quenched with a small amount of water and concentrated under reduced pressure. Tetrahydrofuran (10 mL × 2) was added to the concentrate and the mixture was concentrated again under reduced pressure. The residue was used directly in the next step of the reaction.

[0527] LC-MS m / z (ESI): 245.20 [M+H] + .

[0528] Step 5: Synthesis of Compound 28

[0529] The compound 28-6 obtained in the previous step (0.224 mmol, calculated as 100% yield) was dissolved in dimethyl sulfoxide (10 mL), and compound 25-3 (98 mg, 0.335 mmol) and diisopropylethylamine (173 mg, 1.34 mmol) were added sequentially. Under nitrogen protection, the mixture was heated to 60 °C and reacted for 16 h. The reaction was confirmed by LCMS to be complete. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a yellow solid (compound 28, 62 mg, yield: 59.82%). 1H NMR (400MHz, DMSO-d6): δ9.27 (s, 1H), 8.16 (d, 2H), 7.61 (d, J = 8.2Hz, 1H), 7. 39(d,2H),3.93(t,J=4.8Hz,4H),3.64-3.49(m,1H),3.16(t,J=4.1Hz,2H),2 .98(s,2H),2.74(t,J=4.1Hz,2H),2.57(t,J=5.0Hz,4H),2.40(s,3H),1.86- 1.74(m,4H),1.53-1.41(m,2H),1.40-1.28(m,2H),1.27-1.19(m,1H).LC-MS m / z (ESI): 464.40 [M+H] + .

[0530] Example 29. Synthesis of Compound 29

[0531] Step 1: Synthesis of Compound 29-1

[0532] Compound 15-10 (600 mg, 2.59 mmol) and Boc-piperazine (681 mg, 3.66 mmol) were added to a reaction flask, followed by ethylene glycol dimethyl ether (6 mL) and triethylamine (569 mg, 5.62 mmol). Under nitrogen protection, the mixture was heated to 60 °C and reacted for 18 h with stirring. LC-MS analysis confirmed the reaction was complete. The reaction solution was concentrated, and the residue was dissolved in ethyl acetate (30 mL) and water (30 mL). After stirring, the mixture was separated. The aqueous phase was extracted with ethyl acetate (20 mL × 2). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (eluent: ethyl acetate / n-heptane = 0%–50%, v / v) to give a yellow solid (compound 29-1, yield 512 mg, 51.82%). LC-MS m / z (ESI): 382.30 [M+H] + .

[0533] Step 2: Synthesis of Compound 29-2

[0534] Compound 29-1 (512 mg, 1.34 mmol) was added to a reaction flask, followed by the addition of a 4 mol / L solution of 1,4-dioxane (20 mL, 80 mmol). The mixture was reacted under nitrogen atmosphere at room temperature for 1 h. LC-MS was used to confirm the complete reaction of the starting material. The reaction solution was concentrated under reduced pressure, and 1,4-dioxane (20 mL × 2) was added to the residue, followed by further concentration under reduced pressure to give a yellow solid (compound 29-2, 495 mg, yield: 100%). LC-MS m / z (ESI): 282.30 [M+H] + .

[0535] Step 3: Synthesis of Compound 29-4

[0536] Compound 29-3 (2.50 g, 11.05 mmol) was added to a reaction flask, followed by dichloromethane (25 mL) and triethylamine (3.35 g, 33.14 mmol). Under nitrogen protection, the mixture was stirred and cooled to approximately 5 °C. Acetyl chloride (1.30 g, 16.57 mmol) was weighed, diluted with dichloromethane (3 mL), and added dropwise to the above reaction system. After addition, the mixture was allowed to return to room temperature and reacted for 16 h. LC-MS analysis confirmed the reaction was complete. The reaction solution was quenched with water (30 mL), and the organic phase was separated. The organic phase was washed successively with water (30 mL), saturated citric acid (30 mL), water (30 mL), and saturated brine (30 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a yellow solid (compound 29-4), which was used directly in the next step. LC-MS m / z (ESI): 269.20 [M+H]+.

[0537] Step 4: Synthesis of compound 29-5

[0538] The compound 29-4 obtained in the previous step was reacted with 1,4-dioxane-hydrochloride solution (50 mL, 4 mol / L, 200 mmol) at room temperature for 16 h with stirring. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure, and dichloromethane (10 mL) was added to the residue. The mixture was concentrated again under reduced pressure to give a yellow solid (compound 29-5, 2.30 g, two-step yield: 100%). LC-MS m / z (ESI): 169.10 [M+H] + .

[0539] Step 5: Synthesis of compound 29-6

[0540] Compound 29-5 (2.00 g, 9.77 mmol) was added to a reaction flask, along with N,N-dimethylformamide (25 mL) and potassium carbonate (5.40 g, 39.08 mmol). Under nitrogen protection, the mixture was stirred and cooled to approximately 5 °C. Chloroacetyl chloride (2.21 g, 19.54 mmol) was weighed, diluted with N,N-dimethylformamide (5 mL), and added dropwise to the above system. After the addition was complete, the mixture was reacted at 5 °C for 2 h. LCMS analysis confirmed the reaction was complete. Hydrochloric acid (4 mol / L, 20 mL) and saturated saline solution (40 mL) were added dropwise to the reaction solution, and the mixture was stirred for 20 h. No obvious solid precipitation was observed. The reaction solution was then purified by preparative chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm). ID; Mobile phase A: 10 mmol ammonium formate; Mobile phase B: acetonitrile; Gradient: 10%–80% acetonitrile; Flow rate: 80 mL / min; Wavelength: 210 / 254 nm), yielding a yellow viscous solid (compound 29-6, 100 mg, yield: 4.18%). LC-MS m / z (ESI): 245.20 [M+H]+.

[0541] Step 6: Synthesis of Compound 29

[0542] Compound 29-6 (48 mg, 0.20 mmol), compound 29-2 (35 mg, 0.11 mmol), and triethylamine (60 mg, 0.59 mmol) were added to N,N-dimethylformamide (10 mL) and stirred at 60 °C for 4 h. The reaction mixture was analyzed by LCMS to confirm the reaction was complete. The reaction solution was then purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a yellow solid (compound 29, 4.6 mg, yield: 8.5%). 1H NMR (400MHz, DMSO-d6): δ9.26(s,1H),8.13(d,J=8.4Hz,2H),7.90(s,1H),7.74(s,1H),7.25(d,J=8.4Hz,2H),4.00-3.81(m,4H),2.95(s,2H),2. 62-2.55(m,4H),2.06-2.00(m,1H),1.98(s,2H),1.93-1.81(m,4H),1.7 6(s,3H),1.75-1.62(m,4H),1.10-0.99(m,2H),0.82-0.74(m,2H).LC-MS m / z(ESI):490.40[M+H] + .

[0543] Examples 30-34 were prepared according to the method of Example 29, and the compounds shown in Table 5 below were obtained.

[0544] Table 5:

[0545] The compounds obtained in Examples 30-34 1 H NMR and MS are shown in Table 6.

[0546] Table 6:

[0547] Example 35. Synthesis of compound 35-P1 / compound 35-P2

[0548] Step 1: Synthesis of Compound 35-2

[0549] 4-Bromostyrene (5.00 g, 27.47 mmol), difluorobromomethyltrimethylsilane (8.37 g, 41.21 mmol), tetrabutylammonium bromide (0.27 g, 0.82 mmol), and toluene (100 mL) were added sequentially to a reaction flask. The mixture was purged with nitrogen three times and heated to 110 °C for 4 h. GC-MS analysis confirmed the reaction was complete. The mixture was then cooled to room temperature, and water (100 mL) was added. The mixture was stirred to separate the phases. The aqueous phase was extracted with EA (30 mL × 2). The organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure at 50 °C. The crude product was used directly in the next step. GC-MS m / z (EI): 232.00.

[0550] Step 2: Synthesis of Compound 35-3

[0551] The crude compound 35-2, tributyl(1-ethoxyethylene)tin (11.90 g, 25.75 mmol), triethylamine (3.90 g, 38.46 mmol), Pd(dppf)Cl2.DCM (1.00 g, 1.37 mmol), and dioxane (125 mL) were added sequentially to a reaction flask, and the mixture was purged with nitrogen three times. The mixture was heated to 80 °C and reacted for 12 h. GC-MS analysis confirmed the reaction was complete, and the mixture was cooled to room temperature. 2N hydrochloric acid (50 mL) was added, and the mixture was stirred at room temperature for 30 min. The mixture was filtered through diatomaceous earth, and the filter cake was washed with dioxane (20 mL). The filtrate was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a brown oily substance (compound 35-3, 5.30 g, two-step yield 98.5%). GC-MS m / z (EI): 196.10.

[0552] Step 3: Synthesis of compound 35-4

[0553] Compound 35-3 (5.30 g, 27.04 mmol), selenium dioxide (3.8 g, 34.23 mmol), dioxane (35 mL), and water (0.7 mL) were added sequentially to the reaction flask. The mixture was heated to 80 °C and reacted for 12 h. LC-MS analysis confirmed the reaction was complete. The mixture was then cooled to room temperature. The mixture was filtered through a diatomaceous earth liner, and the filter cake was washed with 10 mL of ethyl acetate. The filtrate was concentrated to dryness under reduced pressure at 45 °C. The crude product was used directly in the next step. LC-MS m / z (ESI): 211.10 [M+H] + .

[0554] Step 4: Synthesis of compound 35-5

[0555] Compound 35-5 obtained in the previous step and water (53 mL) were added to the reaction flask, heated to 100 °C and stirred for 1 h, then cooled to 55 °C. A solution of aminourea hydrochloride (3.2 g, 28.8 mmol) and water (27 mL) was added dropwise over 30-50 min. The reaction was maintained at 55 °C for 2 h, and the reaction was confirmed by LC-MS. The mixture was cooled to room temperature, filtered, and the filter cake was washed with water (40 mL). The filter cake was used directly in the next step. LC-MS m / z (ESI): 268.10 [M+H] +

[0556] Step 5: Synthesis of compound 35-6

[0557] The wet product of compound 35-5 obtained in the previous step and water (40 mL) were added to the reaction flask. A solution of sodium hydroxide (1.47 g, 36.75 mmol) and water (6 mL) was added dropwise over 1-2 minutes. The mixture was heated to 55 °C and reacted for 6 hours. LC-MS analysis confirmed the reaction was complete. The mixture was then cooled to room temperature, and acetic acid (approximately 2.7 g) was added dropwise to adjust the pH to 6-7. The mixture was filtered, and the filter cake was washed with water (40 mL). The filter cake was then vacuum dried at 55 °C to obtain a gray solid (compound 35-6, 2.2 g, three-step yield 32.8%). LC-MS m / z (ESI): 250.20 [M+H] +

[0558] Step 6: Synthesis of Compound 35-7

[0559] Compound 35-6 (1.7 g, 6.83 mmol), DMF (0.8 mL), and ethylene glycol dimethyl ether (17 mL) were added sequentially to a reaction flask. The mixture was purged with nitrogen three times, and the temperature was raised to 60 °C with stirring. Thionyl chloride (2.44 g, 20.49 mmol) was added, and the temperature was raised to 70 °C for 3 h. The reaction was confirmed by LC-MS to be complete. The mixture was cooled to room temperature and concentrated to dryness under reduced pressure at 40 °C. The residue was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to give a brown solid (compound 35-7, 1.84 g, yield 24.7%). LC-MS m / z (ESI): 268.10 [M+H] +

[0560] Step 7: Synthesis of Compound 35

[0561] Compound 35-7 (0.45 g, 1.69 mmol), compound 15-5 (0.72 g, 3.38 mmol), diisopropylethylamine (1.09 g, 8.45 mmol), and dimethyl sulfoxide (9 mL) were added sequentially to a reaction flask. The mixture was purged with nitrogen three times, heated to 60 °C, and reacted for 4 h. The reaction was confirmed by LC-MS to be complete. The mixture was then cooled to room temperature, and the reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a yellow solid (compound 35, 0.62 g, yield 71.7%). 1H NMR (400MHz, DMSO-d6): δ9.30(s,1H),8.23(d,2H),7.71(d,J=7.7Hz,1H),7.61(d,J=8.2Hz,1H),7.48(d,2H),3.93(t,J=5.1Hz,4H),3. 67-3.39(m,2H),3.19-3.07(m,1H),2.98(s,2H),2.57(t,J=5.1Hz,4H),2.16-1.97(m,2H),1.93-1.60(m,7H),1.41-1.09(m,4H).LC-MS m / z(ESI):514.40[M+H] + .

[0562] Step 8: Synthesis of Compound 35-P1 / Compound 35-P2

[0563] Compound 35, obtained from the preparative HPLC purification in the previous step, was separated by chiral HPLC (SHIMADZU RFC-40, column: YMC-CHIRAL ART Amylose-C Neo 10μm 250*50mm ID, mobile phase: ethanol / n-hexane, isocratic ratio: 30% ethanol, flow rate: 130mL / min) to obtain compound 35-P1 (RT = 10.32min, 246mg, chiral purity 100%, yield 39.68%) and compound 35-P2 (RT = 12.05min, 238.6mg, chiral purity 97.62%, yield 38.48%). Single-crystal X-ray diffraction analysis confirmed that compound 35-P1 is in the R configuration and compound 35-P2 is in the S configuration.

[0564] Compound 35-P1: 1 H NMR (400MHz, DMSO-d6): δ9.23(s,1H),8.16(d,2H),7.65(d,J=7.7Hz,1H),7.55(d,J=8.2Hz,1H),7.41(d,2H),3.86(t,J=5.1Hz,4H),3. 54-3.40(m,2H),3.11-3.01(m,1H),2.91(s,2H),2.50(t,J=5.1Hz,4H),2.06-1.95(m,2H),1.80-1.60(m,7H),1.32-1.08(m,4H).LC-MS m / z(ESI):514.30[M+H] + .

[0565] Compound 35-P2: 1H NMR (400MHz, DMSO-d6): δ9.31(s,1H),8.23(d,2H),7.72(d,J=7.8Hz,1H),7.62(d,J=8.3Hz,1H),7.47(d,J=8.2Hz,2H),4.00-3.85(m,4H) ,3.64-3.40(m,2H),3.19-3.08(m,1H),2.98(s,2H),2.57(t,J=5.0Hz,4H),2.14-2.01(m,2H),1.85-1.70(m,7H),1.38-1.16(m,4H).LC-MS m / z(ESI):514.40[M+H] + .

[0566] Single-crystal X-ray analysis of compound 35-P1:

[0567] Instrument: Bruker D8 VENTURE dual-microspot single-crystal X-ray diffractometer, ambient temperature 193K, Cu light source, wavelength

[0568] Compound 35-P1 was dissolved in MeOH / H2O and filtered through a 0.45 μm organic filter membrane. The supernatant was placed in a vial. Long, sheet-like crystals were obtained by slow evaporation after sealing the vial at room temperature. Single-crystal analysis was performed. The results showed that compound 35-P1 contains one chiral carbon atom with an absolute configuration of R. The two groups attached to the six-membered ring are located on either side of the cyclohexane ring, exhibiting a trans configuration. The stereoconfiguration of compound 35-P1 is shown below:

[0569] Example 36. Synthesis of Compound 36

[0570] The synthesis of compound 36 follows the preparation method described in Example 1.

[0571] 1H NMR (400MHz, DMSO-d6): δ9.26 (s, 1H), 8.17-8.10 (m, 2H), 7.77-7.72 (m, 1H), 7.69 (d, J = 8.4Hz, 1H), 7.41-7.32(m,1H),7.26(d,J=8.2Hz,2H),6.40-6.33(m,1H),6.28-6.20(m,1H),4.77-4.65(m,1H), 3.94(t,J=4.9Hz,4H),3.80-3.68(m,1H),3.00(s,2H),2.58(t,J=5.0Hz,4H),2.06-1.98(m,1H),1. 94-1.85(m,2H),1.84-1.67(m,4H),1.57-1.43(m,2H),1.11-1.01(m,2H),0.83-0.75(m,2H).LC-MS m / z(ESI):514.40[M+H] + .

[0572] Example 37. Synthesis of Compound 37

[0573] The synthesis of compound 37 follows the preparation method described in Example 28.

[0574] 1 H NMR (400MHz, DMSO-d6): δ9.28(s,1H),8.16(d,J=8.3Hz,2H),7.64(d,J=8.2Hz,1H),7 .28(d,J=8.2,2H),3.94(t,J=4.9Hz,4H),3.64-3.52(m,2H),18(t,J=4.1Hz,2H),3.0 0(s,2H),2.76(t,J=4.1Hz,2H),2.59(t,J=5.0Hz,4H),2.09-2.00(m,1H),1.87-76(m ,4H),1.55-1.43(m,2H),1.42-1.29(m,2H),11-1.02(m,2H),0.85-0.77(m,2H).LC-MS m / z(ESI):490.40[M+H] + .

[0575] Example 38. Synthesis of Compound 38

[0576] Step 1: Synthesis of Compound 38-1

[0577] 4-tert-Butoxycarbonylaminopiperidine (2.00 g, 10.00 mmol), triethylamine (3.03 g, 30.00 mmol), and tetrahydrofuran (30 mL) were added sequentially to a reaction flask, stirred, and cooled to -20 °C. Acetyl chloride (1.18 g, 15.00 mmol) was then added, and the reaction was maintained at -20 °C for 1 h. TLC was used to determine the complete reaction of the starting materials (DCM:MeOH = 5:1, v / v). The reaction solution was concentrated to dryness under reduced pressure at 35 °C, and water (40 mL) and ethyl acetate (50 mL) were added, followed by stirring to separate the layers. The aqueous phase was extracted with ethyl acetate (2 × 200 mL). The organic phases were combined, washed with 5% citric acid (30 mL), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure at 35 °C. A 4 M dioxane chloride solution (20 mL) was then added to the concentrate, and the reaction was carried out at room temperature for 1 h. After LC-MS analysis confirmed the reaction was complete, the reaction solution was concentrated to dryness under reduced pressure at 45°C. The residue was used directly in the next reaction step. LC-MS m / z (ESI): 143.10 [M+H] + .

[0578] Step 2: Synthesis of Compound 38-2

[0579] Compound 38-1 obtained in the previous step, triethylamine (5.05 g, 50 mmol), and tetrahydrofuran (40 mL) were added sequentially to a reaction flask. The mixture was cooled to -20 °C, and then chloroacetyl chloride (1.46 g, 13 mmol) was added. The reaction was maintained at -20 °C for 1 h. LC-MS was used to confirm the completion of the reaction. The mixture was filtered, and the filtrate was concentrated to dryness under reduced pressure at 35 °C and used directly for the next reaction. LC-MS m / z (ESI): 219.10 [M+H] + .

[0580] Step 3: Synthesis of Compound 38

[0581] Compound 38-1 (50 mg, 0.14 mmol), compound 29-2 (62 mg, 0.28 mmol), triethylamine (72 mg, 0.70 mmol), and DMF (5 mL) were added sequentially to the reaction flask. The mixture was purged with nitrogen three times, and the temperature was raised to 50 °C for 12 h. LC-MS was used to confirm the completion of the reaction. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 10%–80% acetonitrile; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a yellowish-brown solid (compound 38, 8.3 mg, yield 12.7%). 1H NMR (400MHz, DMSO-d6): δ9.28(s,1H),8.16(d,J=8.2Hz,2H),7.75(d,J=8.2Hz,1H),7.28(d, 2H),4.27(d,J=13.3Hz,1H),3.95(t,4H),3.91-3.82(m,1H),3.78(d,J=13.8Hz,1H),3.19-3. 07(m,1H),3.02(s,2H),2.77-2.65(m,1H),2.59(t,J=5.1Hz,4H),2.08-2.03(m,1H),2.03-1. 98(m,4H),1.82-1.68(m,2H),1.54-1.20(m,1H),1.12-1.01(m,2H),0.86-0.74(m,2H).LC-MS m / z(ESI):464.40[M+H] + .

[0582] Example 39. Synthesis of Compound 39

[0583] Step 1: Synthesis of Compound 39-1

[0584] Trans-(4-aminocyclohexyl)carbamate tert-butyl ester (compound 28-1, 5.00 g, 23.33 mmol) was added to a reaction flask, followed by acetonitrile (50 mL) and N,N-dimethylformamide (50 mL), and then potassium carbonate (9.67 g, 69.97 mmol). A turbid solution was obtained by stirring. Chloroacetyl chloride (2.77 g, 24.53 mmol) was weighed, diluted with acetonitrile (10 mL), and added dropwise to the above reaction system. After the addition was complete, the reaction system was allowed to react at room temperature for 17 h. LC-MS analysis confirmed the reaction was complete. The mixture was then cooled to room temperature, and the reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm). ID; Mobile phase A: 10 mmol ammonium formate; Mobile phase B: acetonitrile; Gradient: 10-80-95-95 (acetonitrile percentage), elution time: 0-30-30.5-35 min; Flow rate: 80 mL / min; Wavelength: 210 / 254 nm), yielding a white solid (compound 39-1, 820 mg, 12.09%). LC-MS m / z (ESI): 329.20 [M+K] + .

[0585] Step 2: Synthesis of Compound 39-2

[0586] Compound 39-1 (231 mg, 0.79 mmol) and compound 29-2 (210 mg, 0.66 mmol, 1.0 eq) were added to a reaction flask, along with dimethyl sulfoxide (10 mL) and diisopropylethylamine (342 mg, 2.64 mmol). The mixture was then heated to 60 °C for 16 h under nitrogen protection. LC-MS analysis confirmed the reaction was complete. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 25-95-95 (acetonitrile percentage); elution time: 0-30-35 min; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a solid (compound 39-2, 146 mg, yield: 41.25%).

[0587] LC-MS m / z (ESI): 536.50 [M+H] + .

[0588] Step 3: Synthesis of Compound 39-3

[0589] Compound 39-2 (110 mg, 0.21 mmol) was added to a reaction flask, followed by the addition of 1,4-dioxane hydrochloride solution (5 mL, 4 mol / L, 20 mmol). The mixture was stirred at room temperature for 2 h. LCMS analysis showed that the starting material had reacted completely. The reaction solution was concentrated under reduced pressure, and 1,4-dioxane (10 mL × 2) was added to the residue, followed by another concentration under reduced pressure. The residue was then used directly in the next reaction step.

[0590] Step 4: Synthesis of Compound 39

[0591] Compound 39-3 (40 mg, 0.085 mmol) was dissolved in dichloromethane (5 mL), and then triethylamine (54 mg, 0.534 mmol) was added. Under nitrogen protection, the mixture was cooled to -10 °C, and deuterated acetyl chloride (11 mg, 0.135 mmol) was added. The reaction was carried out for 2 h. The reaction was detected by LCMS to indicate that the reaction was complete. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZURFC-40; column: Kromasil ET C18 10 μm 250*50 mm ID; mobile phase A: 10 mmol ammonium formate; mobile phase B: acetonitrile; gradient: 15-85-95-95 (acetonitrile percentage); elution time: 0-30-30.5-35 min; flow rate: 80 mL / min; wavelength: 210 / 254 nm) to obtain a yellow solid (compound 39, 5.4 mg, yield: 48.21%). 1H NMR (400MHz, DMSO-d6): δ9.28(s,1H),8.16(d,2H),7.74(d,J=7.8Hz,1H),7.63(d ,J=8.2Hz,1H),7.28(d,2H),3.94(t,J=5.1Hz,4H),3.62-3.52(m,1H),3.52-3.44( m,1H),3.00(s,2H),2.58(t,J=5.1Hz,4H),2.09-1.99(m,1H),1.85-1.75(m,4H), 1.41-1.29(m,2H),1.28-1.15(m,2H),1.10-1.03(m,2H),0.85-0.76(m,2H).LC-MS m / z (ESI): 481.40 [M+H] + .

[0592] Example 40. Synthesis of Compound 40

[0593] Step 1: Synthesis of Compound 40-1

[0594] Compound 29-2 (150 mg, 0.53 mmol), methyl 2-bromoacetate-d2 (100 mg, 0.64 mmol), potassium carbonate (260 mg, 1.88 mmol), and N,N-dimethylformamide (8 mL) were added to a reaction flask. The mixture was heated to 70 °C and stirred for 1 hour. After cooling to room temperature, the mixture was diluted with water and extracted with ethyl acetate (8 mL × 3). The organic phase was collected and washed once with saturated brine (8 mL). The organic phase was collected again and concentrated to dryness under reduced pressure to obtain the crude product. No purification was required for the next reaction. LC-MS m / z (ESI): 356.30 [M+H] + .

[0595] Step 2: Synthesis of Compound 40-2

[0596] The crude product of compound 40-1 obtained in the previous step, lithium hydroxide (64 mg, 2.67 mmol), tetrahydrofuran (10 mL), methanol (10 mL), and water (10 mL) were added sequentially to the reaction flask. Under N2 protection, the mixture was stirred overnight at 50 °C. LC-MS analysis showed no residual starting material. The reaction solution was concentrated under reduced pressure to remove the organic solvent. The residue was adjusted to neutral with 10% citric acid, and a solid precipitated. The solid was filtered, dried under reduced pressure, and a yellow solid (compound 40-2, 120 mg, two-step yield: 65.9%) was obtained. LC-MS m / z (ESI): 342.30 [M+H] + .

[0597] Step 3: Synthesis of Compound 40

[0598] Compound 40-2 (50 mg, 0.146 mmol), N-((1R,4R)-4-aminocyclohexyl)acetamide hydrochloride (34 mg, 0.176 mmol), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (65 mg, 0.162 mmol), N,N-dimethylformamide (2 mL), and N,N-diisopropylethylamine (80 mg, 0.596 mmol) were added sequentially to the reaction flask. The mixture was purged with nitrogen three times and reacted at room temperature for 1 h. After the reaction was completed, the reaction solution was purified by preparative liquid chromatography (SHIMADZU RFC-40, column: Kromasil ET C18 10μm 250*50mm ID, mobile phase: aqueous phase (10mmol / L ammonium formate) and acetonitrile, gradient ratio: acetonitrile 15%-70%, flow rate: 75mL / min) to obtain a light yellow solid (compound 40, 46mg, yield 65.5%). 1 H NMR (400MHz, DMSO-d6): δ9.29(s,1H),8.16(d,J=8.3Hz,2H),7.75(d,J=7.8Hz,1 H),7.64(d,J=8.2Hz,1H),7.28(d,J=8.2Hz,2H),3.99-3.86(m,4H),3.64-3.44( m,2H),2.59(t,J=5.0Hz,4H),2.05(tt,J=8.4,5.0Hz,1H),,1.85-1.73(m,7H),1 .41-1.29(m,2H),1.29-1.16(m,2H),1.10-1.04(m,2H),0.84-0.77(m,2H).LC-MS m / z (ESI): 480.40 [M+H] + .

[0599] Example 41. Synthesis of Compound 41

[0600] The synthesis steps were performed according to the preparation method of Example 40, resulting in compound 41.

[0601] 1H NMR (400MHz, DMSO-d6): δ9.28(s,1H),8.21-8.05(m,2H),7.59(d,J=8.1Hz,1H),7.31-7.21(m,2H),3.93(ddd,J=11 .2,7.3,5.5Hz,5H),2.59(t,J=5.1Hz,4H),2.04(tt,J=8.3,5.0Hz,1H),1.16-1.04(m,8H),0.83-0.74(m,2H).LC-MS m / z(ESI):383.30[M+H] + .

[0602] Example 42. Synthesis of Compound 42

[0603] Step 1: Synthesis of Compound 42-2

[0604] 4-(5-bromopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester (compound 42-1, 300 mg, 0.87 mmol), (4-cyclopropylphenyl)boronic acid (142 mg, 0.87 mmol), catalyst Xphos-Pd-G4 (75 mg, 0.087 mmol), and potassium carbonate (364 mg, 2.63 mmol) were dissolved in toluene (3 mL) and water (0.3 mL). The reaction was carried out under nitrogen protection at 110 °C for 16 h. The reaction was monitored by LC-MS. After the reaction was complete, the mixture was filtered, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: ethyl acetate / n-heptane = 0–15%) to give a yellow solid (compound 42-2, 250 mg, yield 75%). LC-MS m / z (ESI): 380.20 [M+H] +

[0605] Step 2: Synthesis of Compound 42-3

[0606] Compound 42-2 (250 mg, 0.66 mmol) was dissolved in 1,4-dioxane (2 mL), and 1 mL of dioxane hydrochloride solution was added. The mixture was stirred at room temperature for 3 h, and the reaction was monitored by LC-MS. After the reaction was complete, the reaction solution was concentrated under reduced pressure, and the residue was used directly in the next step. LC-MS m / z (ESI): 280.20 [M+H] +

[0607] Step 3: Synthesis of Compound 42

[0608] Compound 42-3 (150 mg, 0.53 mmol) and compound 1-5 (123 mg, 0.53 mmol) were dissolved in dimethyl sulfoxide (3 mL), and N,N-diisopropylethylamine (342 mg, 2.65 mmol) was added. The mixture was reacted at 60 °C for 16 h, and the reaction was detected by LC-MS. After the reaction was completed, the reaction solution was purified by preparative liquid chromatography (preparation method: SHIMADZU-40, column: Kromasil ET C18 10 μm 250*40 mm ID, mobile phase: aqueous phase (10 mmol / L ammonium formate) and acetonitrile, gradient ratio: acetonitrile 10%-75%, flow rate: 75 mL / min) to obtain a white solid (compound 42, 123 mg, yield 48%). 1 HNMR (400MHz, DMSO-d6): δ8.25(s,2H),7.70(d,J=7.8Hz,1H),7.57(dd,J=8 .7,6.9Hz,3H),7.45(s,1H),7.20-7.12(m,2H),3.60-3.43(m,2H),3.25(s, 4H),2.95(s,2H),2.58(t,J=5.0Hz,4H),1.95(tt,J=8.3,5.0Hz,1H),1.81- 1.68(m,7H),1.37-1.10(m,4H),1.04-0.92(m,2H),0.77-0.66(m,2H).LC-MS m / z(ESI):476.40[M+H] + .

[0609] Example 43. Synthesis of Compound 43

[0610] Compound 39-3 (43 mg, 91 μmol) was added to a reaction flask, followed by dichloromethane (6 mL) and triethylamine (129 mg, 1.28 mmol). Under nitrogen protection, the mixture was stirred and cooled to -10 °C. Isobutyryl chloride (15 mg, 0.141 mmol) was dissolved in dichloromethane (1 mL) and added dropwise to the above reaction system. The mixture was stirred at -10 °C for 1 h. LC-MS analysis confirmed the reaction was complete. The reaction solution was purified by preparative liquid chromatography (instrument: SHIMADZU RFC-40; column: Kromasil ET C18 10 μm 250*50 mm). ID; Mobile phase A: 10 mmol ammonium formate; Mobile phase B: acetonitrile; Gradient: 20-90-95-95 (acetonitrile percentage), elution time: 0-30-30.5-35 min; Flow rate: 80 mL / min; Wavelength: 210 / 254 nm), yielding a yellow solid (compound 43, 13.5 mg, yield: 29.31%). 1H NMR (400MHz, DMSO-d6): δ9.26(s,1H),8.13(d,J=8.3Hz,2H),7.58(dd,J=17.2,8.0Hz,2H),7.25(d,J=8.4H z,2H),4.04-3.80(m,4H),3.55(d,J=8.0Hz,1H),3.51-3.42(m,1H),2.97(s,2H),2.61-2.54(m,4H),2.36- 2.25(m,1H),2.02(ddd,J=13.1,8.4,5.0H,1H),1.77(d,J=9.8Hz,4H),1.33(dd,J=23.9,11.1Hz,2H),1.22 (dd,J=23.1,11.3Hz,2H),1.05(td,J=6.4,4.3Hz,2H),0.98(s,3H),0.96(s,3H),0.83-0.73(m,2H).LC-MS m / z(ESI):506.40[M+H] + .

[0611] Example 44. Synthesis of Compound 44

[0612] The synthesis steps of compound 44 are the same as those in Example 40.

[0613] 1 H NMR (400MHz, DMSO-d6): δ9.28 (s, 1H), 8.19-8.12 (m, 2H), 7.74 (d, J = 7.8Hz, 1H),7.64(d,J=8.3Hz,1H),7.31-7.24(m,2H),3.94(t,J=5.0Hz,4H),3.64- 3.45(m,2H),2.59(t,J=5.0Hz,4H),2.04(m,1H),1.83-1.76(m,4H),1.42-1 .29(m,2H),1.28-1.14(m,2H),1.12-1.03(m,2H),0.85-0.76(m,2H).LC-MS m / z(ESI):483.40[M+H] + .

[0614] Biological evaluation:

[0615] Test Example 1

[0616] Stable monoclonal cell lines expressing human CYP11B2 and CYP11B1 were constructed using the human renal leiomyoma cell line G-402. Using 11-deoxycorticosterone (a substrate of CYP11B2) and 11-deoxycortisol (a substrate of CYP11B1) as substrates, the effects of the compounds on the enzyme activities of CYP11B2 and CYP11B1 were assessed by LC-MS / MS detection of changes in the levels of the enzyme catalytic products aldosterone (a catalytic product of CYP11B2) and cortisol (a catalytic product of CYP11B1). Cellular enzyme activity inhibition experiments were performed using DMEM / F12 medium containing 2.5% charcoal-treated FBS and appropriate concentrations of substrate (1 μM 11-deoxycorticosterone or 1 μM 11-deoxycortisol). Cells were incubated in McCoy's 5A medium containing 10% FBS. 4 Log-phase cells stably expressing human CYP11B2 or CYP11B1 were seeded into 96-well plates and incubated for 24 h. The culture supernatant was removed, and the medium was replaced with DMEM / F12 containing 2.5% charcoal-treated FBS. Serially diluted compounds were added and incubated for 1 h, followed by the addition of 1 μM 11-deoxycorticosterone or 1 μM 11-deoxycortisol and incubation for 16 h. The supernatant was collected, and the concentration of the expected product (CYP11B2 product: aldosterone; CYP11B1 product: cortisol) was analyzed by LC-MS / MS. The results are shown in Tables 7-1 and 7-2.

[0617] Reference drugs: Baxdrostat (N-[(8R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinoline-6-yl)-5,6,7,8-tetrahydroisoquinoline-8-yl]propionamide) is disclosed in WO2013079452 and purchased from MedChemExpress; Lorundrostat (N-[(1r,4r)-4-acetamidocyclohexyl]-2-{4-[5-(4-methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-yl}acetamide) is disclosed in CN106232587 and prepared according to the method disclosed in CN106232587.

[0618] Table 7-1:

[0619] Table 7-2:

[0620] As can be seen from the test results in Tables 7-1 and 7-2, the compounds disclosed herein have excellent inhibitory activity against human CYP11B2, and at the same time, they have higher selectivity compared to CYP11B1.

[0621] In particular, compounds 15 and 26 exhibited inhibitory activity against human CYP11B2 comparable to or superior to that of the control compound Lorundrostat, while showing more than 3,000 times selectivity compared to CYP11B1.

[0622] Compound 35-P2 exhibits superior inhibitory activity against human CYP11B2 compared to the control compound Lorundrostat, and also demonstrates more than 4000 times selectivity compared to CYP11B1.

[0623] Test Example 2: Pharmacokinetic Determination of Compounds in Mice and Rats

[0624] Using mice and rats as test animals, the compound of the present invention was administered by gavage (PO), and plasma samples were collected at specific time points. The concentration of the compound in plasma was detected by LC-MS / MS, and PK parameters were calculated to evaluate the pharmacokinetic behavior of the compound of the present invention in mice and rats.

[0625] Test protocol:

[0626] 1.1 Experimental animals:

[0627] Mice: CD-1 mice, male, purchased from Vital River.

[0628] Rats: Sprague–Dawley rats, male, purchased from Vital Rivers.

[0629] 1.2 Administration

[0630] 1.2.1 Drug administration to mice:

[0631] Administration method: oral gavage (PO); Administration information: 3 mice, the dose was 10 mg / kg, the volume of administration was 10 mL / kg, and the solvent was 15% PEG400 + 80% (5% TPGS aqueous solution) + 5% (1% HPMC K100LV aqueous solution).

[0632] Drug-administered compounds: Compound 15, Compound 35-P2, and Lorunderstat from the examples.

[0633] 1.2.2 Drug administration to rats:

[0634] Administration method: oral gavage (PO); Administration information: 3 rats, the dose was 5 mg / kg, the volume of administration was 5 mL / kg, and the solvent was 15% PEG400 + 80% (5% TPGS aqueous solution) + 5% (1% HPMC K100LV aqueous solution).

[0635] Drug-administered compounds: Compound 15, Compound 35-P2, and Lorunderstat from the examples.

[0636] 1.3 Experimental Equipment:

[0637] The centrifuge, pipettes, and vortex mixer were all purchased from Eppendorf.

[0638] 1.4 Sample Collection:

[0639] In mice, 0.03 mL of venous blood was collected at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after drug administration. In rats, 0.2 mL of venous blood was collected at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after drug administration. The samples were placed in EDTA-K2 tubes and centrifuged at 4000g for 5 min at 4℃ to separate the plasma. The plasma was then stored at -80℃ for later analysis.

[0640] 1.5 Sample preparation:

[0641] Mouse plasma sample processing:

[0642] 1) Add 200 μL of acetonitrile to 10 μL of plasma sample, vortex mix and centrifuge for 15 minutes.

[0643] 2) After treatment, the supernatant was diluted with water and the concentration of the analyte was analyzed by LC / MS / MS.

[0644] Rat plasma sample processing:

[0645] 1) Add 200 μL of acetonitrile to 50 μL of plasma sample, vortex mix and centrifuge for 15 minutes.

[0646] 2) After treatment, the supernatant was diluted with water and the concentration of the analyte was analyzed by LC / MS / MS.

[0647] 2. Experimental Results:

[0648] Pharmacokinetic parameters were calculated using WinNonlin 8.3. Table 8 shows the pharmacokinetic parameters for mouse PO, and Table 9 shows the pharmacokinetic parameters for rat PO. Among them, C... max T represents the maximum blood drug concentration. 1 / 2 MRT represents the terminal elimination half-life. 0-last represents the average residence time, and AUC represents the area under the curve during drug administration.

[0649] Table 8: Pharmacokinetic parameters of the compounds in mice

[0650] Conclusion: As shown in Table 8, the compounds disclosed in this study exhibit favorable pharmacokinetic properties in mice. Among them, compounds 15 and 35-P2 show superior pharmacokinetic properties compared to the control compound Lorundrostat.

[0651] Table 9: Pharmacokinetic parameters of the compound in rats

[0652] Conclusion: As shown in Table 9, the compounds disclosed herein exhibit favorable pharmacokinetic properties in rats. Among them, compounds 15 and 35-P2 possess superior pharmacokinetic properties compared to the control compound Lorundrostat.

[0653] It should be noted that although the technical solutions of this disclosure have been described with specific examples, those skilled in the art will understand that this disclosure should not be limited thereto.

[0654] The various embodiments of this disclosure have been described above. These descriptions are exemplary and not exhaustive, nor are they limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terminology used herein is chosen to best explain the principles, practical application, or technical improvements to the embodiments in the market, or to enable others skilled in the art to understand the embodiments disclosed herein.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotopic labels: in, Ring A is selected from 5-10 membered heteroaromatic rings and 5-10 membered saturated or partially saturated heteroalicylic rings, each of which contains 1-3 N atoms; R 1 selected from H, halogen, -SF5, cyano, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C3-C6cycloalkyl, and 3-6 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S, each of said cycloalkyl or heterocycloalkyl optionally substituted with 1-2 groups selected from halogen, C1-C6alkyl, C1-C6haloalkyl, and C1-C6alkoxy; m is selected from 0, 1, 2, and 3; If it exists, each R 2 Each is independently selected from halogens, hydroxyl groups, and C1-C6 alkyl groups; L is selected from *-C(R) 7 R 8 )-C(=O)-, *-OC(=O)- and *-C(=O)-C(R 7 R 8 )-, where one end of the "*" mark is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms to which they are attached, they form a 3-5 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups and C1-C6 alkoxy groups; Ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; Each Each bond can be a single bond or a double bond independently, and they cannot both be double bonds at the same time; X 1 Selected from C, CH, CR 3 and N, X 2 Selected from CH2, CHR 3 NH, CH and N, X 3 Selected from CH2, CHR 3 NH, CH and N, under the condition that: X 1 X 2 X 3 They are not both N at the same time, and they satisfy the valence bond rule; Y is selected from CR 6 and N; if they exist, R 6 Selected from H, halogens, and hydroxyl groups; n is selected from 0, 1, and 2; If it exists, each R 3 Each is independently selected from C1-C6 alkyl and oxo groups; or, When n=2, there are 2 R 3 Attached to the same C atom of ring B and interconnected with each other, forming an 8-12 member saturated or partially saturated spirocyclic or heterospirocyclic ring together with ring B, wherein each spirocyclic or heterospirocyclic ring is optionally substituted by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or, When n=2, there are 2 R 3 Each atom is attached to two adjacent carbon atoms of ring B and interconnected with them, forming a 7-10 saturated or partially saturated fused aliphatic ring or fused heteroaliphatic ring together with ring B. Each fused aliphatic ring or fused heteroaliphatic ring is optionally substituted with 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups, and C1-C6 alkoxy groups; or... When n=2, there are 2 R 3 Each of the two non-adjacent C atoms of ring B is connected to each other and together with ring B forms a 7-10 saturated or partially saturated bridged ring or heterobridged ring, wherein each bridged ring or heterobridged ring is optionally replaced by 1-3 groups selected from halogens, hydroxyl groups, C1-C6 alkyl groups and C1-C6 alkoxy groups; R 4 For H; R 5 The alkyl group is a C1-C6 alkyl group, a C1-C6 deuterated alkyl group, a C1-C6 haloalkyl group, a C4-C11 cycloalkyl group, a C5-C9 bridged cycloalkyl group, or a 4-11 membered heterocyclic alkyl group containing 1-3 heteroatoms selected from N, O, and S. Each of the cycloalkyl, bridged cycloalkyl, or heterocyclic alkyl groups is optionally surrounded by 1-3 atoms selected from halogen, cyano, hydroxy, oxo, amino, mercapto, 3-8 membered heterocyclic, 5-10 membered heteroaryl, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)O. The heterocyclic or heteroaryl group is substituted with a group selected from N, O, and S and optionally substituted with a group selected from halogen, oxo, hydroxyl, C1-C6 alkyl, and C1-C6 alkoxy groups; or, R 4 R 5 The N atoms bonded to them together form 4-11 membered heterocyclic groups, which additionally contain 0-3 heteroatoms selected from N, O, and S and optionally surrounded by 1-3 heteroatoms selected from halogen, cyano, hydroxyl, oxo, amino, mercapto, 3-8 membered heterocyclic groups, 5-10 membered heteroaryl groups, R', -OR', -SR', -NHR', -NR'2, -NHC(=O)R', -NHS(=O)2R', -NHC(=O)OR', -C(=O)R', -S(=O)2R', - The 3-8-membered heterocyclic group or 5-10-membered heteroaryl group is substituted with a group selected from N, O and S and optionally substituted with a group selected from 1-2 groups selected from halogen, oxo, hydroxyl, C1-C6 alkyl and C1-C6 alkoxy groups; If present, each R' is independently selected from C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl and C3-C6 cycloalkyl.

2. The compound according to claim 1, or its pharmaceutically acceptable salt, stereoisomer, tautomer, solvate, prodrug, or isotope-labeled form, characterized in that, R 1 The group is selected from H, F, Cl, Br, -SF5, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy and C3-C6 cycloalkyl, wherein the cycloalkyl group is optionally substituted by 1-2 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy; Preferably, R 1 Selected from -SF5 and C3-C6 cycloalkyl groups, wherein the cycloalkyl group is optionally replaced by 1-2 groups selected from halogens and C1-C6 alkyl groups; More preferably, R 1 Selected from -SF5, cyclopropyl and 2,2-difluorocyclopropyl.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled compounds, characterized in that, Ring A is selected from a 5-6 membered heteroaromatic ring, wherein the heteroaromatic ring contains 1-3 N atoms; Preferably, ring A is selected from pyridine ring, pyridazine ring, pyrazine ring, 1,2,4-triazole ring, 1,2,3-triazine ring, 1,2,4-triazine ring, 1,3,5-triazine ring and partially saturated pyrazolopyrrole ring; More preferably, ring A is in, One end of the marker is connected to the benzene ring. One end of the marker is connected to ring B; If they exist, each R 2 The components are independently selected from halogens, hydroxyl groups, and C1-C4 alkyl groups, with F, Cl, and Br being preferred; m is selected from 0, 1, and 2, with 0 and 1 being preferred.

4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, characterized in that, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H, deuterium, and C1-C6 alkyl groups, or R 7 R 8 Together with the C atoms to which they are attached, they form a 3-5 membered aliphatic ring, which is optionally replaced by 1-3 groups selected from halogens, C1-C6 alkyl groups and C1-C6 alkoxy groups; Preferably, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 Each is independently selected from H and deuterium, or R. 7 R 8 Together with the C atoms they are attached to, they form cyclopropane groups; More preferably, L is *-C(R) 7 R 8 )-C(=O)-, where one end of the * marker is connected to ring B, and the other end is connected to -NR 4 R 5 Connection; R 7 R 8 For H.

5. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, characterized in that, Ring B is in, One end of the mark is connected to ring A. One end of the marker is connected to L; if it exists, each R 3 Independently selected from C1-C6 alkyl and oxo groups; n is selected from 0, 1, and 2.

6. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label, characterized in that, R 4 For H; R 5 for Cy is selected from C4-C6 saturated aliphatic rings and C5-C8 bridged rings; T is -C(=O)- or -S(=O)2-; R 13 For H and R 14 It is a C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl, or, R 13 and R 14 Interconnection makes Formation of 4-6 membered heterocyclic groups; Preferably, R 4 For H; R 5 for Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl, C1-C4 deuterated alkyl, or C1-C4 haloalkyl, or, R 13 and R 14 Interconnection makes form More preferably, R 4 For H; R 5 for Cy is T is -C(=O)-; R 13 For H and R 14 It is a C1-C4 alkyl or a C1-C4 deuterated alkyl, or, R 13 and R 14 Interconnection makes form 7. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope-labeled form, characterized in that, The compound of formula (I) is shown in formula (I-3): Among them, L and R 1 R 3 R 4 R 5 The definition of n is as described in any one of claims 1-6.

8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled compounds, characterized in that, The compound of formula (I) is shown in formula (I-9): Among them, Cy, T, R 1 R 4 R 7 R 8 R 13 and R 14 The definition is as described in any one of claims 1-6.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, its stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled compounds, characterized in that, The compound of formula (I) is shown in formula (I-5): Wherein, R' is defined as R in claim 8. 14 Definition; R 1 The definition is as described in claim 1 or 2.

10. The following compounds or their pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, prodrugs, or isotope-labeled compounds:

11. A pharmaceutical composition comprising the compound according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug, or isotope label; Preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients; More preferably, the pharmaceutically acceptable excipients include fillers, disintegrants, surfactants, and solubilizers.

12. A pharmaceutical formulation comprising a compound according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof, a stereoisomer, a tautomer, a solvate, a prodrug or an isotope label, or a pharmaceutical composition according to claim 11; Preferably, the pharmaceutical preparation includes tablets, capsules, granules, sugar-coated pills, powders, lozenges, powder injections, liquid preparations, and suppositories.

13. The use of the compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug or isotopic label, or the pharmaceutical composition of claim 11, or the pharmaceutical formulation of claim 12, in the preparation of a medicament for regulating (preferably inhibiting) 11-β hydroxylase and / or aldosterone synthase; Preferably, the drug is a drug for selectively regulating (preferably inhibiting) aldosterone synthase.

14. The use of the compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug or isotopic label, or the pharmaceutical composition of claim 11, or the pharmaceutical formulation of claim 12, in the preparation of a medicament for the treatment, prevention or relief of diseases mediated by aldosterone synthase; Preferably, the related diseases mediated by aldosterone synthase include primary aldosteronism, secondary aldosteronism, hypertension, heart failure, cardiomyopathy, cardiac hypertrophy (including left ventricular hypertrophy), myocardial infarction, myocardial necrosis, myocardial ischemia-reperfusion injury, coronary artery disease, myocardial or vascular fibrosis or remodeling (including cardiovascular fibrosis and remodeling associated with hypertension and / or endothelial dysfunction), restenosis, vascular wall thickening, arteriosclerosis, renal failure (including chronic renal failure), acute kidney injury, chronic kidney disease, renal fibrosis, nephropathy (including diabetic nephropathy), hypokalemia, obesity, metabolic syndrome, sleep apnea syndrome, retinopathy (including diabetic retinopathy), liver disease, lipid metabolism disorders, sympathetic hyperactivity, sudden and / or periodic edema, headache, anxiety disorders, and depressive disorders; More preferably, the primary aldosteronism includes unilateral or bilateral adrenal adenoma, unilateral or bilateral adrenal hyperplasia, aldosterone-producing adrenal carcinoma, unilateral adrenal multinodular aldosteronism, glucocorticoid-responsive aldosteronism, familial aldosteronism, and ectopic aldosterone-producing tumors. More preferably, the secondary aldosteronism includes hypertension caused by estrogen preparations, renovascular hypertension, pregnancy-induced hypertension, malignant hypertension, pheochromocytoma, congestive heart failure, pseudohypoaldosteronism, chronic liver disease (including cirrhosis) with ascites, and hyperaldosteronism. More preferably, the hypertension includes primary hypertension, secondary hypertension (including renovascular hypertension, renal parenchymal hypertension, primary aldosteronism, pheochromocytoma, sleep apnea syndrome, Cushing's syndrome, drug-induced hypertension, aortic stenosis and hyperparathyroidism), uncontrolled hypertension, refractory hypertension, intractable hypertension, obesity-related hypertension and mineralocorticoid-related hypertension. More preferably, the heart failure includes congestive heart failure, left ventricular failure, right ventricular failure, systolic dysfunction, and diastolic dysfunction. More preferably, the hyperaldosteronism is hyperaldosteronism caused by improper use of drugs such as laxatives or diuretics, nephrotic syndrome, Barth syndrome, or Gitmann syndrome.

15. The use of the compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, its stereoisomer, tautomer, solvate, prodrug or isotope label, or the pharmaceutical composition according to claim 11, or the pharmaceutical preparation according to claim 12, in the preparation of a medicament for treating, preventing or alleviating hypertension; Preferably, the hypertension is uncontrolled hypertension, refractory hypertension, or intractable hypertension; Preferably, the drug further comprises one or more active therapeutic agents selected from diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers; More preferably, the diuretic is selected from indapamide, clopamamide, chlorthalidone, hydrochlorothiazide, mefcitrate, metoprazone, and metecriptine; More preferably, the angiotensin-converting enzyme inhibitor is selected from captopril, enalapril, perindopril, benazepril, fosinopril, cilazapril, ramipril, midapril, lisinopril, and benazepril; More preferably, the angiotensin II receptor blocker is selected from olmesartan, candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan; More preferably, the calcium channel blocker is selected from amlodipine besylate, nifedipine, diltiazem, nimodipine, verapamil, isradipine, felodipine, nicardipine, nisodipine, clovidipine, dihydropyridine, lercanidipine, nifedipine, sinidipine, manidipine, miradipine, benprodipine, barnidipine, nivardipine, golopamil, lidocaine, areradipine, and dotalizine.